Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-26T20:59:26.222Z Has data issue: false hasContentIssue false

Potential therapeutic targets shared between leishmaniasis and cancer

Published online by Cambridge University Press:  04 February 2021

Sajad Rashidi
Affiliation:
Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Celia Fernández-Rubio
Affiliation:
Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea 1, University of Navarra, ISTUN Instituto de Salud Tropical, 31008Pamplona, Spain
Raúl Manzano-Román
Affiliation:
Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain
Reza Mansouri
Affiliation:
Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
Reza Shafiei
Affiliation:
Vector-borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran
Mohammad Ali-Hassanzadeh
Affiliation:
Department of Immunology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran
Afshin Barazesh
Affiliation:
Department of Microbiology and Parasitology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
Mohammadreza Karimazar
Affiliation:
Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Gholamreza Hatam*
Affiliation:
Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Paul Nguewa*
Affiliation:
Department of Microbiology and Parasitology, IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea 1, University of Navarra, ISTUN Instituto de Salud Tropical, 31008Pamplona, Spain
*
Authors for correspondence: Gholamreza Hatam, E-mail: [email protected]; Paul Nguewa, E-mail: [email protected]
Authors for correspondence: Gholamreza Hatam, E-mail: [email protected]; Paul Nguewa, E-mail: [email protected]

Abstract

The association of leishmaniasis and malignancies in human and animal models has been highlighted in recent years. The misdiagnosis of coexistence of leishmaniasis and cancer and the use of common drugs in the treatment of such diseases prompt us to further survey the molecular biology of Leishmania parasites and cancer cells. The information regarding common expressed proteins, as possible therapeutic targets, in Leishmania parasites and cancer cells is scarce. Therefore, the current study reviews proteins, and investigates the regulation and functions of several key proteins in Leishmania parasites and cancer cells. The up- and down-regulations of such proteins were mostly related to survival, development, pathogenicity, metabolic pathways and vital signalling in Leishmania parasites and cancer cells. The presence of common expressed proteins in Leishmania parasites and cancer cells reveals valuable information regarding the possible shared mechanisms of pathogenicity and opportunities for therapeutic targeting in leishmaniasis and cancers in the future.

Type
Review Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s), 2021. Published by Cambridge University Press

Introduction

Leishmaniasis and cancer

Leishmaniasis is a group of vector-borne diseases caused by intracellular protozoan belonging to the genus Leishmania. Annually, approximately 1.5–2 million new cases are reported worldwide being 310 million people at risk. The mortality rate of the disease varies from 40 000 to 70 000 cases per year (Torres-Guerrero et al., Reference Torres-Guerrero, Quintanilla-Cedillo, Ruiz-Esmenjaud and Arenas2017). Clinical manifestations vary depending on the Leishmania species and the immune status of the host, among others. The clinical symptoms of cutaneous leishmaniasis (CL) are mostly restricted to the skin lesions with diverse appearances, from localized to body extended wounds or mucosal affectations. However, visceral leishmaniasis (VL) is characterized by severe organic symptoms and might lead to death (Den Boer et al., Reference Den Boer, Argaw, Jannin and Alvar2011; Torres-Guerrero et al., Reference Torres-Guerrero, Quintanilla-Cedillo, Ruiz-Esmenjaud and Arenas2017). Malnutrition, acquired immune deficiency syndrome and cancer are important factors that affect the host immune system and lead to more severe clinical symptoms in patients with leishmaniasis (Ezra et al., Reference Ezra, Ochoa and Craft2010; Nweze et al., Reference Nweze, Nweze and Onoja2020).

Cancer is a group of diseases involving an abnormal growth of cells, which tend to proliferate in an uncontrolled way and, in some cases, metastasize. It can affect almost any tissue of the body. After coronary artery diseases, cancer is the second major cause of death in humans. Each year, the global mortality rate of cancers is estimated at 8.2 million deaths and approximately 14.1 million new cases are being reported (Torre et al., Reference Torre, Siegel, Ward and Jemal2016). The clinical manifestations of cancers are wide-ranging and the immunosuppression is a critical side-effect to be considered during the management of cancers (Blagosklonny, Reference Blagosklonny2013).

The possible association of leishmaniasis and malignancies (cancers)

Although smoking is one of the principal causes of cancer development, infections are also a risk factor, mainly those caused by bacteria (Helicobacter pylori) (Nguewa et al., Reference Nguewa, Villa, Notario, Villa and Vinas2016) and viruses (Human papillomavirus, Hepatitis B and C viruses, Herpes virus, Epstein–Bar virus and human T-cell leukaemia-lymphoma virus) (Liao, Reference Liao2006). However, certain parasitic infections (by Opisthorchis, Clonorchis, Theileria and Schistosoma) can also raise the risk of developing some types of cancers and may contribute to the appearance of malignancies which makes them possible models to study host–parasite interactions and mechanisms of cancer (De Martel et al., Reference De Martel, Ferlay, Franceschi, Vignat, Bray, Forman and Plummer2012; Tretina et al., Reference Tretina, Gotia, Mann and Silva2015; Cheeseman and Weitzman, Reference Cheeseman and Weitzman2017).

The association of leishmaniasis and malignancies in human and animal models has been highlighted in previous studies (Kopterides et al., Reference Kopterides, Mourtzoukou, Skopelitis, Tsavaris and Falagas2007; Ferro et al., Reference Ferro, Palmieri, Cavicchioli, Zan, Aresu and Benali2013; Al-Kamel, Reference Al-Kamel2017). Due to the relatively similar clinical manifestations in certain leishmaniasis forms and cancers, misdiagnosis might occur in the clinic (Toogeh et al., Reference Toogeh, Shirkoohi, Nickbin, Najafi, Salimi, Farsi and Ferdowsi2010; Schwing et al., Reference Schwing, Pomares, Majoor, Boyer, Marty and Michel2019). For instance, the diagnosis of childhood leukaemia should be carefully differentiated from VL, especially in endemic areas where the concurrent occurrence had been reported (Vasconcelos et al., Reference Vasconcelos, Azevedo-Silva, Thuler, Pina, Souza, Calabrese and Pombo-de-Oliveira2014). Similarly, cutaneous and mucocutaneous leishmaniasis may be clinically misdiagnosed as squamous cell carcinoma (SCC) (Ramos et al., Reference Ramos, Munez, García-Domínguez, Martinez-Ruiz, Chicharro, Banos, Suarez-Massa and Cuervas-Mons2015; Oetken et al., Reference Oetken, Hiscox, Orengo and Rosen2017). These data point out the possible similar association in clinical manifestations of leishmaniasis and tumoural alterations. Moreover, failures at epigenetic level to maintain integrity of chromosomes is one contributing factor in cancer and Leishmania parasites also modulate and destabilize the host chromatin structure leading to potential changes in relevant immune-related genes and responses (Sarkar et al., Reference Sarkar, Leung, Baguley, Finlay and Askarian-Amiri2015; Afrin et al., Reference Afrin, Khan and Hemeg2019; Dacher et al., Reference Dacher, Tachiwana, Horikoshi, Kujirai, Taguchi, Kimura and Kurumizaka2019).

In addition, numerous compounds with anti-tumour activity have exhibited potent leishmanicidal properties (Table 1). The use of common drugs for the treatment of leishmaniasis and cancer might further propose and highlight the presence of plausible similarities in their molecular mechanisms of action, immunopathobiology and therapeutic targets in both diseases (Table 2) (Kopterides et al., Reference Kopterides, Mourtzoukou, Skopelitis, Tsavaris and Falagas2007; Miguel et al., Reference Miguel, Yokoyama-Yasunaka, Andreoli, Mortara and Uliana2007, Reference Miguel, Yokoyama-Yasunaka and Uliana2008; Moulisha et al., Reference Moulisha, Kumar and Kanti2010; Toogeh et al., Reference Toogeh, Shirkoohi, Nickbin, Najafi, Salimi, Farsi and Ferdowsi2010). Furthermore, chemotherapies administered against some forms of cancer display immune dysfunctions and/or immunosuppression. An example is bortezomib, a proteasome inhibitor which decreases the dendritic cells’ (DCs) activity, the number of T lymphocytes and interferon (IFN) gamma production (Nucci and Anaissie, Reference Nucci and Anaissie2009). This immunosuppressive effect may lead to leishmaniasis development as an opportunistic infection in antitumour-treated patients but also in immunocompetent ones leading to similar symptoms (Piro et al., Reference Piro, Kropp, Cantaffa, Lamberti, Carillio and Molica2012; Cencini et al., Reference Cencini, Lazzi and Fabbri2015; Torti et al., Reference Torti, Pulini, Morelli, Bacci and Di Bartolomeo2015; Schwing et al., Reference Schwing, Pomares, Majoor, Boyer, Marty and Michel2019). Additionally, a synergistic relationship between Leishmania parasites and cancer cells has been highlighted (Morsy, Reference Morsy2013). Now, case reports and clinical observations suggest that leishmaniasis may be a risk factor for certain cancers and that cancer immunosuppression may facilitate Leishmania infections (Morsy, Reference Morsy2013; Liao et al., Reference Liao, Jin, Yu and Jiang2018; Nicolas et al., Reference Nicolas, Elliott Koury, Salibi, Nehme, Mitri, El Sayegh, Rached and Khoury2018; Carrillo-Larco et al., Reference Carrillo-Larco, Acevedo-Rodriguez, Altez-Fernandez, Ortiz-Acha and Ugarte-Gil2019; Claudio et al., Reference Claudio, Alessandro, Luca, Jacopo and Katia2019). However, a comprehensive review regarding common expressed proteins in Leishmania parasites and cancer cells is lacking. Therefore, reviewing and highlighting such functional proteins might reveal valuable information regarding the possible shared mechanisms of pathogenicity and possible therapeutic targets in leishmaniasis and cancers in the future.

Table 1. Some common compounds used against cancer and leishmaniasis

Table 2. Possible functions of several common proteins expressed in Leishmania parasites and cancer cells and plausible inhibitors/drugs against such proteins

Drugs for the treatment of leishmaniasis and cancer with common signalling processes

Drug repurposing is an extensively strategy used to identify new microbicidal compounds including leishmanicidal agents. The effect of antitumour chemical compounds in leishmaniasis treatment might suggest the existence of possible similar mechanisms of pathogenicity and common therapeutic targets in Leishmania parasites and cancer cells. Selenocompounds have demonstrated antitumour properties blocking the mammalian target of rapamycin (mTOR) pathway (Ibanez et al., Reference Ibanez, Agliano, Prior, Nguewa, Redrado, Gonzalez-Zubeldia, Plano, Palop, Sanmartin and Calvo2012) and reduced Leishmania parasite burden during ‘in vitro’ assays. Furthermore, these compounds were able to reduce the expression of leishmanial genes involved in cell cycle, resistance to treatment and virulence at the mRNA level (Fernández-Rubio et al., Reference Fernández-Rubio, Campbell, Vacas, Ibañez, Moreno, Espuelas, Calvo, Palop, Plano and Sanmartin2015). Similarly, naphtilamide derivatives which were previously synthesized as antitumour agents (Karelia et al., Reference Karelia, Sk, Singh, Gowda, Pandey, Ramisetti, Amin and Sharma2017), decreased intracellular amastigotes burden, caused cell cycle arrest and diminished the topoisomerase-2 (TOP II), mini-chromosome maintenance complex (MCM4) and proliferating cell nuclear antigen (PCNA) mRNA levels (Fernández-Rubio et al., Reference Fernández-Rubio, Larrea, Guerrero, Herrero, Gamboa, Berrio, Plano, Amin, Sharma and Nguewa2019). Anti-cancer and anti-leishmaniasis effects of herbal compounds such as pentacyclic triterpenoid are well known (Moulisha et al., Reference Moulisha, Kumar and Kanti2010). Fatty acids from natural sources are inhibitors of therapeutic targets in cancer cells and Leishmania parasites (Carballeira et al., Reference Carballeira, Montano, Cintrón, Márquez, Rubio, Prada and Balaña-Fouce2011, Reference Carballeira, Morales-Guzman, Alvarez-Benedicto, Torres-Martinez, Delgado, Griebenow, Tinoco, Reguera, Perez-Pertejo and Carbajo-Andres2018; Carballeira, Reference Carballeira2013).

Moreover, a set of compounds described as antitumoural drugs also exhibited leishmanicidal activities. Alkylating antineoplastic agents such as cisplatin are inductors of cell death in both, tumour cells and parasites (Fuertes et al., Reference Fuertes, Alonso and Pérez2003; Nguewa et al., Reference Nguewa, Fuertes, Iborra, Najajreh, Gibson, Martínez, Alonso and Pérez2005). Miltefosine (hexadecylphosphocholine, HePC), an alkyl phospholipids compound, has been originally considered for breast cancer and other solid tumours’ treatment. Two compounds of the alkylphosphocholine group, octadecyl-phosphocholine and hexadecylphosphocholine-miltefosine (HePC), have been found to have antineoplastic activity. The mechanism of antitumour action of these compounds was involved in the inhibition of substrate phosphorylation by protein kinase C (PKC) [triggering programmed cell death (apoptosis)]. The presence of PKC on Leishmania membrane led to the further investigations on such compounds against CL. It has been indicated that miltefosine inhibits the biosynthesis of the glycosyl phosphatidyl inositol receptor, a vital molecule for Leishmania intracellular survival. Moreover, this compound interferes with the synthesis of leishmanial-phospholipase (PL) and PKC. The metabolic action of miltefosine affects the biosynthesis of glycolipids and membrane glycoproteins of the Leishmania parasite, leading to apoptosis (Sundar and Olliaro, Reference Sundar and Olliaro2007; Perez et al., Reference Perez, Fuertes, Nguewa, Castilla and Alonso2008; dos Santos Nogueira et al., Reference dos Santos Nogueira, Avino, Galvis-Ovallos, Pereira-Chioccola, Moreira, Romariz, Molla and Menz2019; Fernández-Rubio et al., Reference Fernández-Rubio, Larrea, Guerrero, Herrero, Gamboa, Berrio, Plano, Amin, Sharma and Nguewa2019). Another example is tamoxifen (as a triphenylethylene), a breast cancer drug that has shown an appropriate efficacy in the treatment of leishmaniasis (Miguel et al., Reference Miguel, Yokoyama-Yasunaka, Andreoli, Mortara and Uliana2007, Reference Miguel, Yokoyama-Yasunaka and Uliana2008). Due to the activity of tamoxifen as an oestrogen receptor modulator, this drug has been used in the prevention and treatment of breast cancer. However, it has been elucidated that many biological effects of tamoxifen are independent of the oestrogen machinery, including modulation of calmodulin, kinases and caspases, inhibition of the acidification of intracellular organelles, interference in ceramide metabolism, and partitioning into lipids where it exerts membrane fluidizing and antioxidant activities. Oestrogen receptor-modulated responses are not present in Leishmania parasites. On the other hand, tamoxifen is able to inhibit the acidification of organelles in different cell types in an oestrogen-independent pathway. It seems that tamoxifen modifies the intravacuolar pH of Leishmania-infected macrophages inducing a condition where the drug activity against the Leishmania is increased (Miguel et al., Reference Miguel, Yokoyama-Yasunaka, Andreoli, Mortara and Uliana2007, Reference Miguel, Yokoyama-Yasunaka and Uliana2008). In addition, camptothecin and its analogues target topoisomerase IB (TOP IB) and inhibit in Leishmania the activity of this relaxing enzyme for supercoiled DNA. Similarly, indenoisoquinolines, which are also TOP IB poisons, initially developed as antitumour compounds (Antony et al., Reference Antony, Kohlhagen, Agama, Jayaraman, Cao, Durrani, Rustum, Cushman and Pommier2005), are able to decrease parasite burden ‘in vitro’ and ‘in vivo’ in a mouse model (Balaña-Fouce et al., Reference Balaña-Fouce, Prada, Requena, Cushman, Pommier, Álvarez-Velilla, Escudero-Martínez, Calvo-Álvarez, Pérez-Pertejo and Reguera2012). Furthermore, quinone derivatives that act as antitumour agents, showed anti-leishmanial activity through different mechanisms of action, including TOP II and trypanothione reductase inhibition (Sett et al., Reference Sett, Basu, Ghosh and Das1992; Mukherjee et al., Reference Mukherjee, Das, Kole, Karmakar, Datta and Das2004; Singh and Dey, Reference Singh and Dey2007; Shukla et al., Reference Shukla, Patra and Dubey2011).

Immunological coincidences between leishmaniasis and cancer

Investigations have indicated the effect of Leishmania parasites on the immune system of patients with cancer thus triggering the modulation of anti-cancer immunity. In 2011, Kumar et al. highlighted the role of Leishmania in mutual modulation of the immune system in a patient with Hodgkin's lymphoma (Kumar et al., Reference Kumar, Daga, Kamble, Sothwal, Singh, Nayak and Raizada2011). It's clear that in both diseases the host immune response is critical for the disease outcome. In this sense, immune checkpoints are essential for the regulation of the immune system homoeostasis and metastasis in cancer (Safarzadeh et al., Reference Safarzadeh, Alizadeh, Beyranvand, Jozaaee, Hajiasgharzadeh, Baghbanzadeh, Derakhshani, Argentiero, Baradaran and Silvestris2020). These are also important factors regulating the function of T-cells and can be differentially modulated during pathogen infections (Cai et al., Reference Cai, Liu, Zhong, Zheng, Xiao, Li, Song, Li, Xu and Wu2020). Leishmaniasis shares several key immunoregulatory features with cancer. Thus, in some forms of leishmaniasis, a number of important immune checkpoint molecules have also been identified (Kumar et al., Reference Kumar, Chauhan, Ng, Sundar and Engwerda2017). Cytotoxic T-lymphocyte-associated protein 4 is one of the differentially induced immune checkpoints upon infection that may be targeted to ameliorate disease progression (Viana et al., Reference Viana, Magalhães, Giunchetti, Dutra and Gollob2019). These authors state that some Leishmania species induce a more inflammatory profile which also is well-established in cancer progression. Pattern recognition receptor expression and activation have pro-inflammatory effects on the tumour microenvironment via Toll-like receptor (TLR) signalling (McCall et al., Reference McCall, Muccioli and Benencia2020). Leishmania infections have differential capacities to activate TLRs and are able to block the TLR-based pro-inflammatory downstream signals. Parasite-derived microvesicles can activate specific TLR-based downstream immune inhibitory signals via CD200 to evade macrophage defenses and favour infection (Saha et al., Reference Saha, Basu, Guin, Gupta, Mitterstiller, Weiss, Jana and Ukil2019; Sauter et al., Reference Sauter, Madrid, de Assis, Sá-Nunes, Torrecilhas, Staquicini, Pasqualini, Arap and Cortez2019).

Another shared mechanism is type I IFN-driven immunity. IFNs play essential roles in context-specific anti-pathogen responses and act in many immune-related processes in cancer including therapy (Silva-Barrios and Stager, Reference Silva-Barrios and Stager2017; Sprooten et al., Reference Sprooten, Agostinis and Garg2019). Recently, it has been discovered that type I IFNs are involved in the negative regulation of CD4+ T cell responses in patients with VL in order to thus promote their persistence by suppressing anti-parasitic immunity (Kumar et al., Reference Kumar, Bunn, Singh, Ng, de Oca, Rivera, Chauhan, Singh, Faleiro and Edwards2020). It seems that the action of IFNs may be by targeting DCs to suppress consequently priming and/or expansion of Th1 specific cells during the infection. These authors have also stated with animal models the potential of targeting type I IFN signalling to strength protective immunity. In this regard, some molecules of Leishmania major are able to affect DC maturation thus potentially enhancing DC-based vaccines for cancer (Arab et al., Reference Arab, Motamedi and Hadjati2019). Furthermore, live attenuated nonpathogenic Leishmania parasites directly may induce immune-stimulant responses to regress breast cancer grown (Caner et al., Reference Caner, Sadıqova, Erdoğan, Namlıses, Nalbantsoy, Oltulu, Toz, Yiğittürk, Ozkök and Gunduz2020). Interestingly, these attenuated parasites led to a higher percentage of CD4+ and CD8+ T-cells secreting pro-inflammatory cytokines tumour necrosis factor-α (TNF-α), interleukin-12 (IL-12), IFN-γ, inducible nitric oxide synthase and IL-2, and finally, inducing tumour cell death. Cancer therapy is an essential research area and protein kinases are major targets for drugs. The mTOR is a highly conserved serine/threonine protein kinase that is central regulating essential cellular processes and mTOR inhibitors are used in cancer therapy (Chen and Zhou, Reference Chen and Zhou2020). Leishmania infection activates this key host protein kinase pathway via its phosphorylation which have important effect towards host cellular physiology (M2 macrophage phenotype polarization) and parasite survival inside macrophages through down-regulation of the nuclear factor-κB and signal transducer and activator of transcription 3 oncogene factors (Kumar et al., Reference Kumar, Das, Mandal, Verma, Abhishek, Kumar, Kumar, Ghosh and Das2018). Another type of immune-related molecules which regulate diverse cellular processes involved in cancer and leishmaniasis are Ras, small cellular GTPases. Ras mutations are frequently observed in cancers and leukaemia leading to different isoforms. Currently, research data demonstrate that these isoforms are differentially activated by CD40 to modulate effector signals like inflammation playing crucial roles in infectious diseases and tumour regression between others (Nair et al., Reference Nair, Chakraborty, Banerji, Srivastava, Navare and Saha2020). Leishmania infections are able to inhibit CD40-induced N-Ras activation as a survival strategy switching CD40 signalling leading to inhibition of the p38MAPK pathway, the master regulator of transcript stability and tumour progression (Chakraborty et al., Reference Chakraborty, Srivastava, Jha, Nair, Pandey, Srivastava, Kumari, Singh, Krishnasastry and Saha2015; Soni et al., Reference Soni, Anand and Padwad2019).

From potential targets to drug repurposing

Novel shared targets may be identified by analysing proteins that play key roles in each disease. To date, mass spectrometry and functional proteomics along with other integrative-omics and multi-platforms allow shedding some light on the role of these molecules in different diseases (Cowell and Winzeler, Reference Cowell and Winzeler2019; Khan et al., Reference Khan, Ince-Dunn, Suomalainen and Elo2020; Syu et al., Reference Syu, Dunn and Zhu2020). In addition, some biomarkers of diseases seem to have high potential as drug targets, opening avenue for therapeutic screenings (Sharma et al., Reference Sharma, Garg, Sharma, Capalash and Singh2019; Roy et al., Reference Roy, Shrivastava, Srivastav, Shankar and Srivastava2020). Accordingly, we therefore present some functional proteins that may be useful as shared/interchangeable therapeutic targets for the development pipeline of repurposed drugs against leishmaniasis and cancer.

Protein disulphide isomerases (PDIs)

PDIs belong to a group of multifunctional proteins which are located in the endoplasmic reticulum and catalyse the formation of disulphide bonds during protein creation (Ben Khalaf et al., Reference Ben Khalaf, Muylder, Louzir, McKerrow and Chenik2012). In Leishmania parasites, it has been reported the role of these proteins in pathogenicity and survival. Moreover, their potential immunostimulatory property suggests such proteins as possible drug and vaccine targets against leishmaniasis (Achour et al., Reference Achour, Chenik, Louzir and Dellagi2002; Gupta et al., Reference Gupta, Sisodia, Sinha, Hajela, Naik, Shasany and Dube2007; Ben Khalaf et al., Reference Ben Khalaf, Muylder, Louzir, McKerrow and Chenik2012; Jaiswal et al., Reference Jaiswal, Khare, Joshi, Kushawaha, Sundar and Dube2014; Amit et al., Reference Amit, Dikhit, Singh, Kumar, Suman, Singh, Kumar, Thakur, Das and Das2017).

On the other hand, the expression of PDIs can affect the survival, progression and metastasis of cancer. In fact, PDI gene is up-regulated in different cancer types such as lymphoma, brain, ovarian or kidney among others (Xu et al., Reference Xu, Sankar and Neamati2014). PDI inhibitor developments from natural and synthetic compounds have demonstrated their effectiveness and cytotoxicity against tumours and Leishmania parasites (Ben Khalaf et al., Reference Ben Khalaf, Muylder, Louzir, McKerrow and Chenik2012; Xu et al., Reference Xu, Sankar and Neamati2014; Lee, Reference Lee2017). For instance, propynoic acid carbamoyl methyl amides (PACMA) 31, a new irreversible PDI inhibitor, and 16F16, showed significant anticancer activity in in vitro and in vivo ovarian cancer models (Xu et al., Reference Xu, Butkevich, Yamada, Zhou, Debnath, Duncan, Zandi, Petasis and Neamati2012, Reference Xu, Sankar and Neamati2014). The terminal propynoic group of PACMA covalently reacts with the thiol groups of the active-site cysteines in PDI. This interaction also changes the secondary protein structure of PDI. RB-11-ca, arsenic-containing compounds, sulphhydryl reagents, juniferdin and its analogues, quercetin-3-rutinoside, and bacitracin have been identified as possible PDI inhibitors against cancer cells (Xu et al., Reference Xu, Sankar and Neamati2014). Among PDI inhibitor identified against cancer cells, bacitracin inhibited in vitro promastigote growth as well as amastigote propagation inside macrophages with EC50 values of 39 μ m. This compound blocked both reductase and isomerase activities of PDI in Leishmania parasite (Ben Khalaf et al., Reference Ben Khalaf, Muylder, Louzir, McKerrow and Chenik2012).

Superoxide dismutases (SODs)

SODs are considered potential cellular antioxidants in different cells since they are metalloproteins involved in the breakdown of potentially harmful oxygen molecules, preventing tissue damage. For instance, Fe-SOD protects Leishmania against radical superoxide anions using iron as a cofactor (Opperdoes and Szikora, Reference Opperdoes and Szikora2006; Van Assche et al., Reference Van Assche, Deschacht, da Luz, Maes and Cos2011). SODs are proteins encoded by conserved genes in Leishmania parasites and due to their protective function, are considered possible therapeutic and vaccine targets against leishmaniasis (Paramchuk et al., Reference Paramchuk, Ismail, Bhatia and Gedamu1997; Danesh-Bahreini et al., Reference Danesh-Bahreini, Shokri, Samiei, Kamali-Sarvestani, Barzegar-Jalali and Mohammadi-Samani2011; Sanchez-Moreno et al., Reference Sanchez-Moreno, Gomez-Contreras, Navarro, Marin, Ramírez-Macías, Rosales, Campayo, Cano, Sanz and Yunta2015; Martin-Montes et al., Reference Martín-Montes, Plano, Martín-Escolano, Alcolea, Díaz, Pérez-Silanes, Espuelas, Moreno, Marín and Gutiérrez-Sánchez2017; Rashidi et al., Reference Rashidi, Nguewa, Mojtahedi, Shahriari, Kalantar and Hatam2020a).

Alternatively, the deregulation of the redox homoeostasis is implicated in several diseases, among them malignancies. It had been shown that the activity of Zn-SOD, Mn-SOD and Cu-SOD is decreased in cancer cells. Furthermore, in most brain malignant tumours, apoptosis occurs due to the expression of SODs (Younus, Reference Younus2018) and are proteins inducing the progression and metastasis of pancreatic cancer cells (Oberley and Buettner, Reference Oberley and Buettner1979). Due to the multifunctional role of these proteins, several inhibitors have been developed (Wood et al., Reference Wood, Leese, Leblond, Woo, Ganeshapillai, Purohit, Reed, Potter and Packham2001; Dumay et al., Reference Dumay, Rincheval, Trotot, Mignotte and Vayssière2006; Glasauer et al., Reference Glasauer, Sena, Diebold, Mazar and Chandel2014). For instance, diethyldithiocarbamate (DDC) has been known as an inhibitor of Cu- and Zn-SODs. DDC has antagonistic effects on apoptosis by triggering cytochrome c release and caspase inhibition (Dumay et al., Reference Dumay, Rincheval, Trotot, Mignotte and Vayssière2006). In addition, it has been indicated that SOD1 by the small molecule ATN-224 induced cell death in various non-small-cell lung cancers cells (NSCLCs). ATN-224-dependent SOD1 inhibition enhanced superoxide, which decreased the enzyme activity of the antioxidant glutathione peroxidase, causing an increase in intracellular hydrogen peroxide (H2O2) levels (Glasauer et al., Reference Glasauer, Sena, Diebold, Mazar and Chandel2014). 2-Methoxyoestradiol, a naturally occurring metabolic product of 17-beta-oestradiol, is able to inhibit tubulin polymerization and possesses growth inhibitory and cytotoxic activity in vitro and in vivo. 2-Methoxyoestradiol also inhibited SOD in a tetrazolium salt-based enzyme assay, proposed that oestrogen derivatives could be useful starting points for the development of non-toxic, effective enzyme inhibitors (Wood et al., Reference Wood, Leese, Leblond, Woo, Ganeshapillai, Purohit, Reed, Potter and Packham2001). In addition to application in cancer therapy, due to the expression of SODs in Leishmania parasites, the SOD inhibitory property of this compound can be evaluated against these parasites. In 2017, a series of synthesized selenium derivatives showed in vitro leishmanicidal activities against intracellular amastigote and promastigotes forms of Leishmania braziliensis and Leishmania infantum with significant low toxicity on the parasite-infected-macrophages. Surprisingly, the most active selenium compounds were potent inhibitors of Fe-SOD in both parasite species (Martín-Montes et al., Reference Martín-Montes, Plano, Martín-Escolano, Alcolea, Díaz, Pérez-Silanes, Espuelas, Moreno, Marín and Gutiérrez-Sánchez2017). Moreover, since tubulins are expressed in Leishmania parasites and considered appropriate drug targets, the tubulin polymerization inhibitory property of 2-methoxyoestradiol, is another factor that might underline this compound as a possible drug against leishmaniasis (Morgan et al., Reference Morgan, Ahn, Nzimiro, Fotie, Phelps, Cotrill, Yakovich, Sackett, Dalton and Werbovetz2008).

Phospholipase

PLC facilitates the evasion of protozoan parasites from parasitophorous vacuoles and helps to hydrolyse miltefosine in Leishmania parasites. Such critical functions highlight the role of PLC in the pathogenicity of Leishmania parasites (Breiser et al., Reference Breiser, Kim, Fleer, Damenz, Drube, Berger, Nagel, Eibl and Unger1987; Moudy et al., Reference Moudy, Manning and Beckers2001; Dorlo et al., Reference Dorlo, Eggelte, de Vries and Beijnen2012; Rashidi et al., Reference Rashidi, Nguewa, Mojtahedi, Shahriari, Kalantar and Hatam2020a). Other PLs such as PLA2 play major roles in Leishmania parasites virulence and maintenance in vertebrate hosts. It has been indicated that the use of PLA2 inhibitor such as bromoenol lactone (BEL) led to the reduction of lesions size and decreased the load of parasites in skin in the L. amazonensis-infected BALB/c mice. However, the use of such an inhibitor also induced hepatotoxicity in BALB/c mice (Bordon et al., Reference Bordon, Laurenti, Ribeiro, Toyama, Toyama and Passero2018).

PLCs as intermediate signalling factors for epidermal growth factor and ILs conduct regulatory functions in the immunology of cancers. However, the role of these proteins in the evasion of cancer cells from the host immune system remains unknown (Ramazzotti et al., Reference Ramazzotti, Faenza, Follo, Fiume, Piazzi, Giardino, Fini and Cocco2011). The PLC-isoenzyme profile has not been investigated in Leishmania parasites so far. Nevertheless, the different forms of PLC-isoenzymes including PLC-α, PLC-β1, PLC-ε and PLC-γ1 have been characterized in breast cancer (Cai et al., Reference Cai, Sun, Resaul, Shi, Jiang, Satherley, Davies, Ruge, Douglas-Jones and Jiang2017). It has been shown that nuclear phosphoinositide (PI)-PLC-β1 has a role in the generation, progression and resistance to apoptosis of the cancer cells in patients with myelodysplastic syndromes (MDS) (Ramazzotti et al., Reference Ramazzotti, Faenza, Follo, Fiume, Piazzi, Giardino, Fini and Cocco2011). Other results highlighting the up-regulation of PLC-γ1 in the oral potentially malignant lesion (OPL) were correlated with the development of oral cancer (Ma et al., Reference Ma, Zhou, He and Jiang2013). It was demonstrated that PLC-γ is an important marker in the pathogenicity of cancers (Lattanzio et al., Reference Lattanzio, Piantelli and Falasca2013). The identification of PLC-isoenzymes in Leishmania parasites and the elucidation of possible functions of each PLC-isoenzyme regarding the pathogenicity and clinical manifestations of leishmaniasis might become a new approach for the development of leishmaniasis treatment. It has been shown that inhibition of phosphatidylcholine-specific PLC using tricyclodecan-9-yl-potassium xanthate (D609) selectively targeted proliferation and survival of tumour initiating cells in SCC and ovarian cancer cells. This compound prevented cancer cells from entering the S-phase under growth-factor stimulation without cell death induction (Amtmann and Sauer, Reference Amtmann and Sauer1990; Spadaro et al., Reference Spadaro, Ramoni, Mezzanzanica, Miotti, Alberti, Cecchetti, Iorio, Dolo, Canevari and Podo2008; Iorio et al., Reference Iorio, Ricci, Bagnoli, Pisanu, Castellano, Di Vito, Venturini, Glunde, Bhujwalla and Mezzanzanica2010; Cecchetti et al., Reference Cecchetti, Bortolomai, Ferri, Mercurio, Canevari, Podo, Miotti and Iorio2015). Other compounds including aurintricarboxylic acid, 3013, 3017 and U73122 have been also identified as other possible PLC modulators (Bleasdale et al., Reference Bleasdale, Thakur, Gremban, Bundy, Fitzpatrick, Smith and Bunting1990; Huang et al., Reference Huang, Barrett, Hajicek, Hicks, Harden, Sondek and Zhang2013). These compounds can also be evaluated as inhibitors against PLCs in Leishmania parasites and cancer cells.

Tyrosyl-DNA-phosphodiesterase-1 (TDP-1)

TDP-1 is a PL D able to cleave the phosphodiester bond formed between the tyrosine residue of type I TOP and the 3′ phosphate of DNA. TDP-1 is involved in repairing TOP I–DNA complexes stabilized by TOP IB poisons and performs its activity by hydrolysis of the phosphodiester bond (Banerjee et al., Reference Banerjee, Roy, Sen and Majumder2010). TDP-1 has been firstly described in Leishmania donovani. Recently, indenoisoquinoline derivative with dual TOP IB/TDP-1 inhibitory capability has been tested against L. infantum (Gutiérrez-Corbo et al., Reference Gutiérrez-Corbo, Álvarez-Velilla, Reguera, García-Estrada, Cushman, Balaña-Fouce and Pérez-Pertejo2019).

It has been reported the altered expression of TDP-1 in several cancers (Liu et al., Reference Liu, Zhou, Begum, Sidransky, Westra, Brock and Califano2007; Dean et al., Reference Dean, Fam, An, Choi, Shimizu, Jones, Boerkoel, Interthal and Pfeifer2014; Meisenberg et al., Reference Meisenberg, Gilbert, Chalmers, Haley, Gollins, Ward and El-Khamisy2015). Moreover, single nucleotide polymorphisms are associated with poor survival among small cell lung cancer patients (Lohavanichbutr et al., Reference Lohavanichbutr, Sakoda, Amos, Arnold, Christiani, Davies, Field, Haura, Hung and Kohno2017). Due to its repair action mechanism, TDP-1 is related to resistance to TOP I inhibitors during cancer treatments. Therefore, its status in tumours might predict the effectiveness of the TOP I inhibitors used against cancers. TDP-1 constitutes a promising target in cancer treatment; therefore, the development of inhibitors may be useful to improve the efficacy of chemotherapy (Dean et al., Reference Dean, Fam, An, Choi, Shimizu, Jones, Boerkoel, Interthal and Pfeifer2014; Mozhaitsev et al., Reference Mozhaitsev, Zakharenko, Suslov, Korchagina, Zakharova, Vasil'eva, Chepanova, Black, Patel and Chand2019; Khomenko et al., Reference Khomenko, Zakharenko, Chepanova, Ilina, Zakharova, Kaledin, Nikolin, Popova, Korchagina and Reynisson2020; Mamontova et al., Reference Mamontova, Zakharenko, Zakharova, Dyrkheeva, Volcho, Reynisson, Arabshahi, Salakhutdinov and Lavrik2020).

HSP60

HSPs categorize as a group of proteins that are regulated by different cells in response to exposure to stressful conditions. Several members of these proteins exert chaperone functions by facilitating to refold proteins that were destructed or damaged by the cell stress or by stabilizing new proteins to provide correct folding (Dubey et al., Reference Dubey, Prajapati, Swamy and Pachauri2015). The immunostimulatory property of HSP60 and its up-regulation in Leishmania-infected cells and drug-resistant Leishmania strains lead to consider HSP60 as a valuable biomarker in the vaccination design and the treatment of leishmaniasis (Brandau et al., Reference Brandau, Dresel and Clos1995; Celeste et al., Reference Celeste, Angel, Castro, Gidlund and Goto2004; Requena et al., Reference Requena, Montalvo and Fraga2015; Rashidi et al., Reference Rashidi, Mojtahedi, Shahriari, Kalantar, Ghalamfarsa, Mohebali and Hatam2019). During cancer development, HSP60 is overexpressed in advanced breast and serous ovarian cancers (Desmetz et al., Reference Desmetz, Bibeau, Boissiere, Bellet, Rouanet, Maudelonde, Mangé and Solassol2008; Hjerpe et al., Reference Hjerpe, Egyhazi, Carlson, Stolt, Schedvins, Johansson, Shoshan and Avall-Lundqvist2013). The expression of this protective protein leads to the angiogenesis, metastasis and survival of the cancer cells. Mostly, HSP60 exerts its functions by attaching other proteins. For instance, HSP60 promotes neuroblastoma cells survival through clusterin protein inhibition by a linkage to this protein. In addition, HSP60 binds to the β-catenin and induces metastasis in some cancer cells (Tsai et al., Reference Tsai, Yang, Huang, Chang, Chen, Liu, Teng and Wu2009; Chaiwatanasirikul and Sala, Reference Chaiwatanasirikul and Sala2011). The regulation of apoptosis due to the interaction of HSP60 and cyclophilin D in mitochondrion suggests the dual function of HSP60 in cancer cells (Ghosh et al., Reference Ghosh, Siegelin, Dohi and Altieri2010). In human hepatoma Huh-7 cells, through the interaction of HSP60 with the hepatitis C virus, core proteins induce the production of reactive oxygen species (ROS) and increase the apoptosis which is mediated by TNF-α (Sherman and Multhoff, Reference Sherman and Multhoff2007; Kang et al., Reference Kang, Kim, Kim, Lee, Kim, Lee, Choi and Oh2009). Based on the importance of this chaperone in the viability of both Leishmania and cancer cells, and on the existence of inhibitors targeting them (Cappello et al., Reference Cappello, Marino Gammazza, Palumbo Piccionello, Campanella, Pace, Conway de Macario and Macario2014; Stevens et al., Reference Stevens, Abdeen, Salim, Ray, Washburn, Chitre, Sivinski, Park, Hoang and Chapman2019), HSP60 might be consider a promising therapeutic target against these pathologies. Three known antibiotics (suramin, rafoxanide and closantel) and epolactaene and myrtucommulone have been identified as inhibitors of human HSP60 chaperonin (Meng et al., Reference Meng, Li and Xiao2018; Stevens et al., Reference Stevens, Abdeen, Salim, Ray, Washburn, Chitre, Sivinski, Park, Hoang and Chapman2019). The use of suramin, as first-line chemotherapeutic agent, against Trypanosoma brucei rhodesiense and T. brucei gambiense, might suggest the evaluation of this HSP60 inhibitor against leishmanial-HSP60 (Abdeen et al., Reference Abdeen, Salim, Mammadova, Summers, Goldsmith-Pestana, McMahon-Pratt, Schultz, Horwich, Chapman and Johnson2016; Zininga and Shonhai, Reference Zininga and Shonhai2019). Although the exact mechanism action of this compound remains unknown, probably inhibits some glycolytic enzymes (Willson et al., Reference Willson, Callens, Kuntz, Perié and Opperdoes1993; Zininga and Shonhai, Reference Zininga and Shonhai2019). Sinularin, a compound extracted from the coral Sinularia flexibilis, is able to inhibit HSP60 in melanoma cell-A2058 (Su et al., Reference Su, Lin, Chiu, Chen, Su, Cheng, Hwang, Huang and Wu2012). It has been also shown that bortezomib, a proteasome inhibitor, exhibited its anti-tumour efficacy by increasing HSP60 and HSP90 expression on the surface of cancer cells and inducing phagocytosis in experimental model of ovarian cancer (Chang et al., Reference Chang, Hsu, Wu, Yang, Wang, Wu and Hung2012).

HSP90

HSP90 is a molecular chaperone important to the stability, folding and activity of over 200 proteins responsible for tumour initiation, development and metastasis. This protein is important for survival and proliferation of protozoan parasites during their intracellular mammalian stage. Since the ATPase activity executed in the N-terminal domain of HSP90 is critical for chaperone functions, HSP90 inhibitors capable to prevent ATP hydrolysis are expected to inhibit HSP90, leading to protein degradation and cell death, making this chaperone an attractive putative therapeutic target for cancer and leishmaniasis treatment (R Woodford et al., Reference R Woodford, Dunn, Ciciarelli, Beebe, Neckers and Mollapour2016; Palma et al., Reference Palma, Ferreira, Petersen, Dias, de Menezes, de Magalhães Moreira, Hernandes and Veras2019; Batista et al., Reference Batista, Ramos, Tassone, Leitão, Montanari, Botta, Mori and Borges2020). 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) is an inhibitor of HSP90, which has been investigated in the treatment of cancer such as solid tumours and leukaemia. Alternatively, geldanamycin, and its analogues, 17-dimethylamino ethylamino-17-demethoxygeldanamycin (17-DMAG) and 17-AAG, may show a promising therapeutic activities against leishmaniasis (binding to the N-terminal domain of leishmanial-HSP90). However, the delivery of 17-AAG is difficult because of its poor aqueous solubility (Palma et al., Reference Palma, Ferreira, Petersen, Dias, de Menezes, de Magalhães Moreira, Hernandes and Veras2019; Pires et al., Reference Pires, Magalhaes, Ferrante, de Souza Rebouças, Nguewa, Severino, Barral, Veras and Formiga2020). Moreover, several molecules including Glb02, Glb08, Glb11, Glb16, Glb25 and Glb27 have been suggested as leishmanial-HSP90 inhibitors via binding to the N-terminal region of this protein (Batista et al., Reference Batista, Ramos, Tassone, Leitão, Montanari, Botta, Mori and Borges2020).

Aldehyde dehydrogenase (ALDH)

ALDHs are a group of enzymes found in all subcellular compartments that transform aldehydes to carboxylic acids. In Leishmania, ALDH is located in the mitochondrion (mALDH) and is overexpressed in the promastigote forms compared to the amastigotes (Saxena et al., Reference Saxena, Lahav, Holland, Aggarwal, Anupama, Huang, Volpin, Myler and Zilberstein2007). It has been suggested as a protective protein against oxidative stress during glucose limitation in these parasites (Feng et al., Reference Feng, Feistel, Buffalo, McCormack, Kruvand, Rodriguez-Contreras, Akopyants, Umasankar, David and Jardim2011). Its expression significantly decreases in long culture of Leishmania and mALDH might be related to virulence (Magalhaes et al., Reference Magalhaes, Duarte, Mattos, Martins, Lage, Chavez-Fumagalli, Lage, Menezes-Souza, Regis and Alves2014). Although different ALDH-isoenzymes have been identified in NSCLCs, the expression of such isoenzymes is unknown in Leishmania (Kang et al., Reference Kang, Lee, Hong, Lee, Ahn, Ahn, Seong, Lee, Jang and Hong2016). The low expression of ALDH in normal IMR-90 human lung cells and in Leishmania spp. with attenuated infectivity may highlight the major role of ALDH in the pathogenicity of cancer and leishmaniasis (Bringaud et al., Reference Bringaud, Peris, Zen and Simpson1995; Chavali et al., Reference Chavali, Whittemore, Eddy, Williams and Papin2008; Brocker et al., Reference Brocker, Lassen, Estey, Pappa, Cantore, Orlova, Chavakis, Kavanagh, Oppermann and Vasiliou2010; Feng et al., Reference Feng, Feistel, Buffalo, McCormack, Kruvand, Rodriguez-Contreras, Akopyants, Umasankar, David and Jardim2011; Kang et al., Reference Kang, Lee, Hong, Lee, Ahn, Ahn, Seong, Lee, Jang and Hong2016). The high level of ALDH has been reported in drug-resistant cancer stem cells (Januchowski et al., Reference Januchowski, Wojtowicz and Zabel2013; Clark and Palle, Reference Clark and Palle2016; Vassalli, Reference Vassalli2019). It has also been shown that the use of N,N-diethylaminobenzaldehyde (DEAB) and a combination of gossypol (a pan-ALDH inhibitor) and phenformin leads to cancer cell death (Kang et al., Reference Kang, Lee, Hong, Lee, Ahn, Ahn, Seong, Lee, Jang and Hong2016; Jiménez et al., Reference Jiménez, Pequerul, Amor, Lorenzo, Metwally, Avilés, Parés and Farrés2019). The antiparasitic efficacy of gossypol, as an ALDH inhibitor, has been previously highlighted (Koppaka et al., Reference Koppaka, Thompson, Chen, Ellermann, Nicolaou, Juvonen, Petersen, Deitrich, Hurley and Vasiliou2012). A recent study has identified potential anticancer agents, as potent multi-ALDH isoform inhibitors, increased lipid peroxidation, ROS activity and toxic aldehyde accumulation, and also causing increased apoptosis and G2/M phase cell cycle arrest (Dinavahi et al., Reference Dinavahi, Gowda, Bazewicz, Battu, Lin, Chitren, Pandey, Amin, Robertson and Gowda2020). Such inferred data from cancer cells might clarify the possible function of ALDH in drug-resistant Leishmania strains and suggest the use of ALDH-isoform inhibitors not only for cancer treatment (Dinavahi et al., Reference Dinavahi, Gowda, Bazewicz, Battu, Lin, Chitren, Pandey, Amin, Robertson and Gowda2020), but also as a promising strategy for therapeutic assessments against leishmaniasis.

Topoisomerases (TOPs)

TOPs are a group of enzymes that catalyse changes in the DNA topology during replication, transcription, recombination and genome repair. Firstly, they repeatedly can cut and join phosphodiester bonds from the phosphate deoxyribose structure which harbouring nitrogenous bases encoding genetic message. Secondly, they allow other DNA chains to pass between the temporary formed tails, by using energy from the nucleotide linkage and bind covalently to 3′ or 5′-DNA end (Wang, Reference Wang2002; Pommier et al., Reference Pommier, Sun, Shar-yin and Nitiss2016).

TOP IB: Type IB TOPs cut one DNA strand and covalently join to 3′ end. Two types of TOP IB inhibitors have been described: type I inhibitors or poisons, which stabilize the cleavage complex by creating a ternary complex DNA–enzyme drug; and type II inhibitors which act on the catalytic function of the enzyme. Despite their relevant role in genetic information fidelity conservation, TOP IB from Leishmania parasites are heterodimer enzymes which deeply differ from those of humans. For this reason, Leishmania TOP IB are considered as potential therapeutic targets. Camptothecins and their derivatives have demonstrated inhibitory activities against these parasitic enzymes (Prada et al., Reference Prada, Alvarez-Velilla, Balana-Fouce, Prieto, Calvo-Alvarez, Escudero-Martínez, Requena, Ordóñez, Desideri and Perez-Pertejo2013). Synthetic indenoisoquinolines are potent TOP IB inhibitors with leishmanicidal activity ‘in vivo’ (Balaña-Fouce et al., Reference Balaña-Fouce, Prada, Requena, Cushman, Pommier, Álvarez-Velilla, Escudero-Martínez, Calvo-Álvarez, Pérez-Pertejo and Reguera2012). Recently, hybrids of isoquinolines and camptothecins have shown their leishmanicidal activity through TOP IB activity inhibition (Reguera et al., Reference Reguera, Álvarez-Velilla, Domínguez-Asenjo, Gutiérrez-Corbo, Balaña-Fouce, Cushman and Pérez-Pertejo2019). Similarly, natural alkaloids and marine fatty acids have been reported as Leishmania TOP IB inhibitors (Carballeira et al., Reference Carballeira, Cartagena, Prada, Rubio and Balaña-Fouce2009, Reference Carballeira, Montano, Cintrón, Márquez, Rubio, Prada and Balaña-Fouce2011, Reference Carballeira, Cartagena, Li, Chen, Prada, Calvo-Alvarez, Reguera and Balaña-Fouce2012a, Reference Carballeira, Cartagena, Sanabria, Tasdemir, Prada, Reguera and Balaña-Fouce2012b, Reference Carballeira, Montano, Alvarez-Velilla, Prada, Reguera and Balaña-Fouce2013; Chowdhury et al., Reference Chowdhury, Mukherjee, Sengupta, Chowdhury, Mukhopadhyay and Majumder2011; Kumar et al., Reference Kumar, Chowdhury, Jatte, Chakrabarti, Majumder, Jha and Mukhopadhyay2015, Reference Kumar, Chowdhury, Sarkar, Chakrabarti, Majumder, Jha and Mukhopadhyay2016; Pérez-Pertejo et al., Reference Pérez-Pertejo, Escudero-Martínez, Reguera, Balaña-Fouce, García, Jambrina, San Feliciano and Castro2019) as well as anticancer compounds (Carballeira et al., Reference Carballeira, Montano, Amador, Rodríguez, Golovko, Golovko, Reguera, Álvarez-Velilla and Balaña-Fouce2016, Reference Carballeira, Morales-Guzman, Alvarez-Benedicto, Torres-Martinez, Delgado, Griebenow, Tinoco, Reguera, Perez-Pertejo and Carbajo-Andres2018).

On the other hand, human TOP I is a monomeric enzyme which has been demonstrated being overexpressed in several cancers (Lynch et al., Reference Lynch, Bronstein and Holden2001; Berney et al., Reference Berney, Shamash, Gaffney, Jordan and Oliver2002; Gouveris et al., Reference Gouveris, Lazaris, Papathomas, Nonni, Kyriakou, Delladetsima, Patsouris and Tsavaris2007; Kümler et al., Reference Kümler, Balslev, Stenvang, Brunner and Nielsen2015). Most of the marketed TOP inhibitors applied for cancer treatment target TOP type II. However, there are camptothecin derivatives approved such as irinotecan, topotecan and belotecan (Hevener et al., Reference Hevener, Verstak, Lutat, Riggsbee and Mooney2018) which use TOP IB as a target.

TOP II: Type II TOPs are homodimeric enzymes responsible for catalysing topological changes in the DNA by transitory break of both nucleotide chains. During this process an intermediate covalent, between 5′-ends and such enzymatic subunits, is formed. Those proteins are conserved in blood parasites such as Plasmodium, Trypanosoma or Leishmania and their mammal hosts. However, the emerging interest on Leishmania TOP II was mainly due to its involvement in the kinetoplast DNA network and its replication. Moreover, TOP II is related to drug resistance in these parasites (Jayanarayan and Dey, Reference Jayanarayan and Dey2003; Sengupta et al., Reference Sengupta, Mukherjee, Das, Mandal, Das, Mukherjee and Majumder2005; Singh et al., Reference Singh, Thakur, Chakraborti and Dey2009). The overexpression of a TOP II-like enzyme activity has highlighted the regulatory function of this putative enzyme in arsenite-resistant L. donovani strains (Jayanarayan and Dey, Reference Jayanarayan and Dey2003). A point mutation, R250G, has been detected in the ATPase domain of the TOP II in arsenite-resistant strain of L. donovani parasite. The variation in the TOP II gene sequence between arsenite-sensitive and -resistant strains is anticipated to be responsible for the varied behaviour of this enzymes in response to antileishmanial/anti-TOP II agents (Singh et al., Reference Singh, Thakur, Chakraborti and Dey2009). As aforementioned, similarly to TOP IB targeting agents, there are two groups of TOP II inhibitors depending of their mode of action, and some of them are even able to target both, type I and type II TOPs (Ray et al., Reference Ray, Sadhukhan, Mandal, Mahato and Majumder1997). For instance, isobenzofuranone derivatives are capable to inhibit Leishmania TOP II linked to DNA (Mishra et al., Reference Mishra, Vinayagam, Saha, Chowdhury, Roychowdhury, Jaisankar and Majumder2014; Chowdhury et al., Reference Chowdhury, Godinho, Vinayagam, Zuma, Silva, Jaisankar, Rodrigues, De Souza and Majumder2018), whereas protoberberine perform its effect by stabilizing TOP II–DNA cleavage complex (Marquis et al., Reference Marquis, Makhey, LaVoie and Olivier2003). Mitonafide had demonstrated its activity on Leishmania nuclear and kinetoplast-TOP II (Slunt et al., Reference Slunt, Grace, Macdonald and Pearson1996). Recently, a mitonafide derivative has shown a Leishmania TOP II inhibitory effect similar to type I inhibitors and at the mRNA level (Fernández-Rubio et al., Reference Fernández-Rubio, Larrea, Guerrero, Herrero, Gamboa, Berrio, Plano, Amin, Sharma and Nguewa2019).

Human TOP II presents two isoforms: alpha (TOP 2A) and beta (TOP 2B) which exhibit differences in their molecular weight, genetic regulation and the location of the active site. TOP II expression in cancer lines has been largely studied (Doyle, Reference Doyle1994). Although TOP 2B isoform is expressed relatively constant throughout the cell cycle in both, normal and transformed cells, TOP 2A has been found abnormally expressed in different cancers such as breast, lung or prostate among others (Giaccone et al., Reference Giaccone, van Ark-Otte, Scagliotti, Capranico, van der Valk, Rubio, Dalesio, Lopez, Zunino and Walboomers1995; Depowski et al., Reference Depowski, Rosenthal, Brien, Stylos, Johnson and Ross2000; Mrklic et al., Reference Mrklic, Pogorelic, Capkun and Tomic2014; Schaefer-Klein et al., Reference Schaefer-Klein, Murphy, Johnson, Vasmatzis and Kovtun2015; An et al., Reference An, Xu, Luo, Zheng, Lu, Yang, Qin, Yuan, Shi and Jiang2018; Liu et al., Reference Liu, Xiong, Lin, Yang, Dang and Chen2018). In fact, there are marketed anticancer drugs targeting TOP II, such as anthracycline and podophyllotoxin derivatives (Hevener et al., Reference Hevener, Verstak, Lutat, Riggsbee and Mooney2018). Etoposide, which belongs to the last group, is the best known TOP II poison, stabilizing DNA cleavage complex. Currently, TOP II molecules continue being a promising therapeutic target against cancer, and numerous research projects have focused on the synthesis of new inhibitors (Liberio et al., Reference Liberio, Sadowski, Davis, Rockstroh, Vasireddy, Lehman and Nelson2015; Karelia et al., Reference Karelia, Sk, Singh, Gowda, Pandey, Ramisetti, Amin and Sharma2017; Jiang et al., Reference Jiang, Zhang, Li, Wang, Dong, Zhang, Chen and Du2018; Yamashita et al., Reference Yamashita, Tahara, Hayakawa, Matsumoto, Wada, Tomioka and Iida2018; Li et al., Reference Li, Jiang, Zhang, Li, Zhao, Zhou, Zhang, Tang, Dong and Huang2018b).

Proliferating cell nuclear antigen

PCNA is a processivity factor for DNA polymerase delta (Pol δ) and epsilon (Pol ɛ). It also interacts with other proteins involved in cell-cycle progression which are not parts of the DNA polymerase complex. PCNA has demonstrated its role in the replication and repair of DNA, chromatin assembly and RNA transcription. Its importance in Leishmania pathology is related to its significant role in drug response in clinical isolates (Tandon et al., Reference Tandon, Chandra, Baharia, Das, Misra, Kumar, Siddiqi, Sundar and Dube2014). In addition, this protein is a potential therapeutic target against leishmaniasis since it showed susceptibility to be inhibited at the mRNA level by selenocompounds (Fernández-Rubio et al., Reference Fernández-Rubio, Campbell, Vacas, Ibañez, Moreno, Espuelas, Calvo, Palop, Plano and Sanmartin2015; Fernández-Rubio et al., Reference Fernández-Rubio, Larrea, Guerrero, Herrero, Gamboa, Berrio, Plano, Amin, Sharma and Nguewa2019). It is known that PCNA is overexpressed in tumour cells, to adapt the high capacity of such cells to exhibit an uncontrolled replication (Naryzhny and Lee, Reference Naryzhny and Lee2007). Interestingly, there are several small molecules, including cell-penetrating peptides, targeting PCNA with promising results against breast cancer and other tumours. For instance, several compounds inhibit the association of PCNA and chromatin, resulting in apoptosis and DNA damage in prostate and lung cancer (Dillehay et al., Reference Dillehay, Lu and Dong2014; Lu and Dong, Reference Lu and Dong2019). A cell penetrating peptide had been described as caspase-dependent apoptosis inductor which increased the activity of antitumour treatments in multiple myeloma cells (Muller et al., Reference Muller, Misund, Holien, Bachke, Gilljam, Våtsveen, Rø, Bellacchio, Sundan and Otterlei2013).

Tubulins

Tubulins are highly conserved dimeric proteins present in all eukaryotes. Alpha-beta (α/β) dimers polymerize to form microtubules, which serve as a skeletal system for living cells and participate in several essential functions, such as mitosis or intracellular transport among others (Montecinos-Franjola et al., Reference Montecinos-Franjola, Chaturvedi, Schuck and Sackett2019). In Leishmania, α-tubulin is a key component of the cytoskeleton, responsible for cell shape and involved in cell division, ciliary and flagellar motility (Ramírez et al., Reference Ramírez, Requena and Puerta2013). In addition, it has been related to drug resistance (Prasad et al., Reference Prasad, Kumar and Dey2000; Jayanarayan and Dey, Reference Jayanarayan and Dey2004). Furthermore, proteomic analyses demonstrated that this protein is more abundant in Sb(III)-resistant Leishmania cell lines (Matrangolo et al., Reference Matrangolo, Liarte, Andrade, de Melo, Andrade, Ferreira, Santiago, Pirovani, Silva-Pereira and Murta2013). Due to its role in Leishmania biology and pathology, α-tubulin has been considered a promising target against leishmaniasis and, consequently, compounds targeting this protein have been tested. Selenocompounds were able to significantly reduced α-tubulin gene expression (Fernández-Rubio et al., Reference Fernández-Rubio, Campbell, Vacas, Ibañez, Moreno, Espuelas, Calvo, Palop, Plano and Sanmartin2015). Podophyllum derived toxins are Leishmania tubulin inhibitors however, those showed discrepancies between protein activity and parasite growth inhibition (Escudero-Martínez et al., Reference Escudero-Martínez, Pérez-Pertejo, Reguera, Castro, Rojo, Santiago, Abad, García, López-Pérez and San Feliciano2017). Such results differ from those of colchicine against trypanosomatids. This potent inhibitor of tubulin polymerization in higher eukaryotes seems to lack activity against these parasites, probably due to conformational changes in the protein which block colchicine access (Luis et al., Reference Luis, Serrano, Hidalgo and Mendoza-León2013).

Alterations in the expression of tubulin are related to drug resistance in different cancers, including breast, lung, ovarian, gastric and prostate (Bernard-Marty et al., Reference Bernard-Marty, Treilleux, Dumontet, Cardoso, Fellous, Gancberg, Bissery, Paesmans, Larsimont and Piccart2002; Hwang et al., Reference Hwang, Hong, Kim, Kim, Choi, Kim, Jung, Shim, Bae and Hwang2013; Jiang et al., Reference Jiang, Yu, Zhou, Wang and Su2013; Tsourlakis et al., Reference Tsourlakis, Weigand, Grupp, Kluth, Steurer, Schlomm, Graefen, Huland, Salomon and Steuber2014; Du et al., Reference Du, Li, Fang, Liu, Wang, Li, Zhou and Wang2015). Depending of their mechanism of action, tubulin inhibitors could be mainly grouped as microtubule-destabilizing agents or microtubule-stabilizing agents (Perez, Reference Perez2009). The firsts are colchicine analogues and vinca alkaloids. The seconds are paclitaxel derivatives. Colchicine analogues bind to the colchicine binding site (CBS), one of the most important pockets for potential tubulin polymerization destabilizers. These compounds inhibit tubulin assembly and suppress microtubule formation (Lu et al., Reference Lu, Chen, Xiao, Li and Miller2012). Nevertheless, currently there are not FDA (Food and Drug Administration) approved tubulin inhibitors targeting the CBS (Li et al., Reference Li, Jiang, Li, Liu, Su and Chen2018a, Reference Li, Jiang, Zhang, Li, Zhao, Zhou, Zhang, Tang, Dong and Huang2018b). Taxanes, such as paclitaxel and its derivatives, bind to the interior surface of microtubules, resulting in their stabilization. Therefore, microtubules stabilization increase, leading to cell cycle arrest and apoptosis (Jordan, Reference Jordan2002; Jordan and Wilson, Reference Jordan and Wilson2004).

Voltage-dependent anion-selective channel protein 1 (VDAC-1)

VDAC-1 forms a large channel in the outer mitochondrial membrane that allows the diffusion of hydrophilic molecules. Apoptosis, metabolic flux and intracellular signalling are also important functions of this porin in eukaryotes. Leishmania parasites use anionic voltage-dependent channels as a transport system for adaption to nutritional stress conditions and pH homoeostasis (Vieira et al., Reference Vieira, Lavan, Dagger and Cabantchik1994; Lawen et al., Reference Lawen, Ly, Lane, Zarschler, Messina and De Pinto2005; Shoshan-Barmatz et al., Reference Shoshan-Barmatz, Israelson, Brdiczka and Sheu2006; Bayrhuber et al., Reference Bayrhuber, Meins, Habeck, Becker, Giller, Villinger, Vonrhein, Griesinger, Zweckstetter and Zeth2008).

In cancer cells, VDAC-1 is a protein with dual function involved in the regulation of survival and mitochondria-mediated apoptosis (Shoshan-Barmatz et al., Reference Shoshan-Barmatz, Krelin, Shteinfer-Kuzmine and Arif2017). It has been shown that the use of VDAC-1-specific small interfering RNA leads to the metabolism alteration and the growth suppression of cancer cells. Moreover, the up-regulation of the VDAC-1 increases the expression of apoptotic proteins such as hexokinase (HK), B-cell lymphoma-xL (Bcl-xL) and Bcl-2 in cancer cells and leads to the growth inhibition of such cells. Ion channel blockers have demonstrated activity against ion channel proteins in both, cancer cells and Leishmania parasites (Ponte-Sucre et al., Reference Ponte-Sucre, Campos, Fernandez, Moll and Mendoza-León1998; Kale et al., Reference Kale, Amin and Pandey2015; Leanza et al., Reference Leanza, Manago, Zoratti, Gulbins and Szabo2016; Reimão et al., Reference Reimão, Mesquita, Ferreira and Tempone2016; Shoshan-Barmatz et al., Reference Shoshan-Barmatz, Krelin, Shteinfer-Kuzmine and Arif2017). Verapamil and nifedipine have been identified as human calcium channel blockers in cancer therapy which had been proposed to have mild anti-leishmanial activity (Kashif et al., Reference Kashif, Manna P, Akhter, Alaidarous and Rub2017). Leishmania donovani Ca2+ ion channel (Ld-CC) has been suggested as potential drug target in leishmaniasis treatment (Kashif et al., Reference Kashif, Manna P, Akhter, Alaidarous and Rub2017). Ld-CC regulates Ca2+ concentration which is involved in several functions such as mitochondrial oxidative metabolism and entry inside the macrophages and flagellar motion. Two ligands, ZINC17287336 and ZINC29590262 were showed highest binding affinity towards Ld-CC. These selected compounds have relatively more binding affinity than verapamil and nifedipine. Since ZINC29590262 has shown poor binding affinity towards the human voltage-dependent L-type calcium channel subunit alpha-1C in comparison with the Ld-CC, this compound can be suggested as an appropriate drug target (40% more binding affinity with Ld-CC than the human-voltage-dependent calcium channel) (Kashif et al., Reference Kashif, Manna P, Akhter, Alaidarous and Rub2017).

Mitochondrial import receptor subunit (TOM-40)

TOM-40 is located at the core of the translocase of the outer membrane (TOM) structure. Data produced by genome sequencing in protozoa has indicated the presence of TOM-40 homologues in Cryptosporidium (Keithly et al., Reference Keithly, Langreth, Buttle and Mannella2005; Umejiego et al., Reference Umejiego, Gollapalli, Sharling, Volftsun, Lu, Benjamin, Stroupe, Riera, Striepen and Hedstrom2008). Recent studies have reported TOM-40 in L. infantum amastigotes, and a protein with low similarity to TOM-40 in Trypanosoma (Zarsky et al., Reference Zarsky, Tachezy and Dolezal2012; Rashidi et al., Reference Rashidi, Mojtahedi, Shahriari, Kalantar, Ghalamfarsa, Mohebali and Hatam2019). Although, the function of TOM-40 in Leishmania is unknown, bioinformatics data of the T. brucei genome for both TOM-40 and VDAC have identified a single open reading frame, with sequence analysis suggesting that TOM-40s and VDACs are ancestrally related and should be classified into the same protein family (the mitochondrial porins) (Pusnik et al., Reference Pusnik, Charrière, Maser, Waller, Dagley, Lithgow and Schneider2009). This information might open an attractive insight about using ion channel blockers against both TOM-40s and VDACs in Kinetoplastida such as Trypanosoma and Leishmania parasites.

As a tumour marker, TOM-40 is up-regulated in ovarian cancer cells and induces the proliferation and metastasis of these cells ‘in vitro’. It seems that TOM-40 increases the replication of cancer cells through regulating the mitochondrial activity and improving cellular energy and redox status (Yang et al., Reference Yang, Shin, Cho, Chung, Lee, Kim and Kang2020). Evidence has shown that the inhibition of TOM-40 expression in ovarian cancer cells leads to a reduction in the proliferation and migration of cancer cells. However, directly targeting TOM-40 may be challenging in clinical application due to its substantial expression in normal cells. Since metformin (first-line therapy for type 2 diabetes) has been already clinically used with lower side-effects, this compound can be an appropriate alternative drug for targeting TOM-40 and the mitochondria (inhibiting mitochondria complex I) in epithelial ovarian cancer (Yang et al., Reference Yang, Shin, Cho, Chung, Lee, Kim and Kang2020). The pathogenic functions of TOM-40 and therapeutic strategy against this target in cancer treatment might persuade the scientists to further investigate the expression and possible functions of TOM-40 in pathogenicity of leishmaniasis.

Ornithine aminotransferase (OAT)

Aminotransferase are important enzymes that are able to transaminase aromatic amino acids. The functions of OAT are related to l-arginine pathways involved in polyamines production (Muxel et al., Reference Muxel, Aoki, Fernandes, Laranjeira-Silva, Zampieri, Acuña, Müller, Vanderlinde and Floeter-Winter2018). Polyamines metabolism is strongly important for Leishmania cell proliferation and infection (Ilari et al., Reference Ilari, Fiorillo, Baiocco, Poser, Angiulli and Colotti2015). For instance, a recent study has evaluated the effect of polyamine depletion in L. donovani mutants lacking ornithine decarboxylase or spermidine synthase. As mentioned in Table 1, DFMO inhibitor of ornithine decarboxylase, the enzyme that catalyses putrescine biosynthesis. Those results suggested that putrescine is not only a precursor metabolite for spermidine formation; it had specific functions for parasite viability and proliferation. These results also elucidated that ornithine decarboxylase inhibition and putrescine depletion was the most promising strategy for targeting polyamine biosynthetic pathway. It seemed that both polyamines (ornithine decarboxylase or spermidine) were required for parasite survival but that the presence of either putrescine or spermidine alone may allow Leishmania parasites to survive in a quiescent-like state for several weeks (Perdeh et al., Reference Perdeh, Berioso, Love, LoGiudice, Le, Harrelson and Roberts2020).

OAT as a β-catenin target gene in the liver is involved in the metabolism of glutamine. It has been shown that in hepatocellular carcinoma (HCC), the expression of OAT is up-regulated and the mechanism of this gene up-regulation is related to the activation of β-catenin signalling (Cadoret et al., Reference Cadoret, Ovejero, Terris, Souil, Levy, Lamers, Kitajewski, Kahn and Perret2002; Colnot et al., Reference Colnot, Decaens, Niwa-Kawakita, Godard, Hamard, Kahn, Giovannini and Perret2004). This information proposed that OAT, β-catenin signalling and the metabolism of glutamine are important factors in carcinogenesis especially in HCC (Cadoret et al., Reference Cadoret, Ovejero, Terris, Souil, Levy, Lamers, Kitajewski, Kahn and Perret2002; Thompson and Monga, Reference Thompson and Monga2007). The existence of inhibitors targeting OAT used to block the proliferation of HCC, may also allow the selection of this transferase as a therapeutic target against Leishmania parasites (Zigmond et al., Reference Zigmond, Ya'acov, Lee, Lichtenstein, Shalev, Smith, Zolotarov, Ziv, Kalman and Le2015).

Selenoproteins and selenoamino acid

Selenoproteins are a group of enzymes bearing selenocysteine in their catalytic domain. Many of the Se-bearing proteins participate in oxidative stress protection as observed in Leishmania parasites (Iribar et al., Reference Iribar, Tosi and Cruz2003; Da Silva et al., Reference Da Silva, Silva-Jardim and Thiemann2014). The use of leishmanial selenoproteins and selenoamino acid (selenomethionine) as therapeutic targets due to their role in modulation and evasion of the host immune responses has been recently suggested (Rashidi et al., Reference Rashidi, Nguewa, Mojtahedi, Shahriari, Kalantar and Hatam2020a, Reference Rashidi, Kalantar, Nguewa and Hatam2020b).

The role of selenoproteins and their metabolites including methylselenol, selenodiglutathione, Se-methylselenocysteine and selenomethionine has been underlined in the metabolism of lung cancer cells (Seng and Tiekink, Reference Seng and Tiekink2012). Such metabolites inhibit protein kinases and alter cell cycle in cancer cells. Furthermore, these metabolites induce the activity of lymphokine-activated killer cells and natural killer cells and finally stimulate the immune system against cancer cells (Seng and Tiekink, Reference Seng and Tiekink2012). The use of leishmanial selenoproteins inhibitors as well as the anti-tumour property of selenoproteins and their metabolites against cancer cells might suggest that such aforementioned compounds represent therapeutic targets for the treatment of leishmaniasis and cancers. Auranofin is gold-containing compound with well-known selenoproteins synthesis inhibitor properties. Its activity has been demonstrated against thioredoxin reductase (TrxRd), a Se-bearing enzyme involved in maintaining the intracellular redox state. In cancer, TrxRd overexpression is related to the aggressiveness of the malignancy (Kahlos et al., Reference Kahlos, Soini, Saily, Koistinen, Kakko, Paakko, Holmgren and Kinnula2001; Lincoln et al., Reference Lincoln, Ali, Tonissen and Clarke2003) and its inhibition lead to apoptosis of tumour cells (You and Park, Reference You and Park2016). Using drug repurposing strategy, auranofin had been tested against parasitic diseases including Leishmania, with promising results. However, this compound seems not to target selenoproteins in these parasites, but rather interact with trypanothione reductase, a key enzyme of Leishmania polyamine-dependent redox metabolism (Ilari et al., Reference Ilari, Baiocco, Messori, Fiorillo, Boffi, Gramiccia, Di Muccio and Colotti2012; Sharlow et al., Reference Sharlow, Leimgruber, Murray, Lira, Sciotti, Hickman, Hudson, Leed, Caridha and Barrios2014; Manhas et al., Reference Manhas, Gowri and Madhubala2016). Nevertheless, the existence of specific selenoproteins inhibitors with effective activities against cancer cells might support the role of leishmanial selenoproteins as therapeutic targets (Yan et al., Reference Yan, Guo, Wang, Mao, Huang and Li2015; Arnér, Reference Arnér2017).

Phosphoglycerate kinase-1 [PGK-1 (PKG-B)]

PGKs are transferases involved in ATP production from ADP and 1,3-diphosphoglycerate. Their involvement in the glycolytic pathway and survival of Leishmania parasites has been previously reported (Hart and Opperdoes, Reference Hart and Opperdoes1984; Blattner et al., Reference Blattner, Swinkels, Dörsam, Prospero, Subramani and Clayton1992; Azevedo et al., Reference Azevedo, Toledo, Defina, Pedrosa and Cruz2015). PGKs (PGK-B) are overexpressed in antimony-resistant strains of Leishmania. Therefore, they might be related to the pathogenicity of these parasites (Blattner et al., Reference Blattner, Helfert, Michels and Clayton1998; Kazemi-Rad et al., Reference Kazemi-Rad, Mohebali, Khadem-Erfan, Saffari, Raoofian, Hajjaran, Hadighi, Khamesipour, Rezaie and Abedkhojasteh2013). Increased level of glycolysis enzymes such as PGK in the antimony resistant Leishmania isolates suggesting resistant strains require higher energy to protect against antimony-induced oxidative stress. Alternatively, the overexpression of such enzyme might lead to enhancing in pyruvate which can remove peroxides and participate to reduce oxidative stress (Biyani et al., Reference Biyani, Singh, Mandal, Chawla and Madhubala2011). In both, Leishmania and mammalian cells, PGKs are encoded by two genes: gene B and gene C, and PGK-1 and PGK-2, respectively (Watson and Littlechild, Reference Watson and Littlechild1990; McKoy et al., Reference McKoy, Badal, Prescott, Lux and Hart1997). Several monosubstituted N6 and N2 adenosine derivatives were selected to screen against T. brucei PGK. Of these, 2-amino-N6-substituted analogues represented appropriate activity against the parasite kinase compared with the N6 compounds that lacked the C2 amino group, although activity was still weak (Merritt et al., Reference Merritt, Silva, Tanner, Stuart and Pollastri2014). Since protein kinase inhibition has been primarily discussed as anti-trypanosomatid strategy in treatment, these proteins such as PGK can further investigated in leishmaniasis.

The importance of PGK-1 in cancer development resides on its involvement in drug-resistance and its dual action depending on the cellular environment. Under intracellular hypoxia conditions, it plays an oncogenic role. However, it decreases tumour growth when it is secreted extracellularly through angiogenesis inhibition (Daly et al., Reference Daly, Wind, Jiang, Sun and Hogg2004; He et al., Reference He, Luo, Zhang, Wang, Zhang, Li, Ejaz and Liang2019). In addition to the metabolic functions of PGK-1 in cancer cells, this enzyme induces and increases the angiostatin formation and leads to the restriction of angiogenesis in tumours. The anti-tumour property of PGK-1 has been shown in Lewis lung carcinoma (LLC-1). It is well known that cyclooxygenase-2 (COX-2), as an important marker of resistance to apoptosis in cancer cells, promotes angiogenesis and metastasis (Tsujii and DuBois, Reference Tsujii and DuBois1995; Tsujii et al., Reference Tsujii, Kawano, Tsuji, Sawaoka, Hori and DuBois1998). Due to the overexpression of PGK-1 in LLC-1, COX-2 is decreased and therefore, cell invasion, prostaglandin E2 and angiogenesis are affected by this mechanism. Finally, the progression of cancer cells is then restricted (Tang et al., Reference Tang, Ho, Cho, Lin, Sun, Chi, Wang, Jhou, Yang and Sun2008; Ho et al., Reference Ho, Tang, Ng, Yang, Leu, Lin, Feng, Sung and Sun2010). Under solid tumours and hypoxia conditions, PGK-1 is the main source of production of ATP. Solid tumour cells use mechanisms that inhibit the production of PGK and decrease the angiostatin formation. Furthermore, other angiogenesis activators such as vascular endothelial cell growth factor are active in solid tumours (Daly et al., Reference Daly, Wind, Jiang, Sun and Hogg2004). Currently, potential PGKs-inhibitors are under development (He et al., Reference He, Luo, Zhang, Wang, Zhang, Li, Ejaz and Liang2019).

Conclusion

The up- and down-regulation of the aforementioned proteins were mostly related to the survival, development, pathogenicity, metabolic pathways and vital signalling in Leishmania parasites and cancer cells. As an interesting issue, the regulation of these markers can be investigated in interactions that can be occurred between Leishmania parasites and cancer cells under ‘in vivo’ and ‘in vitro’ conditions. The reliable validation of the expression of such proteins in Leishmania parasites and cancer cells using further experiments is warranted to subsequently confirm their possible functions. Further investigation of the differentially regulation of common expressed proteins between cancer cells, normal human cells, low-pathogenic and high-pathogenic forms of Leishmania parasites might elucidate novel and attractive information concerning such proteins. The existence of common triggering factors reflects mutual features in the etiopathogenetic mechanisms underlying leishmaniasis and cancer. Given these similarities, lessons learned from strategies against cancer may be relevant to design adequate approaches to reduce and eliminate leishmaniasis. Herein, we focused specifically on the shared mechanisms at protein scale. Taken together, the introduction of common expressed proteins in Leishmania parasites and cancer cells might reveal valuable information regarding the possible common mechanisms of pathogenicity and therapeutic targets in leishmaniasis and cancers. Taking into account that current therapies for neglected diseases are based in drugs lacking effectiveness, the lack of new specific anti-Leishmania compounds and of research focused on this group of diseases, drug repurposing constitutes a useful tool to find effective candidates in leishmaniasis control and elimination. This review reinforces the likely functional similarities between many proteins in cancer and parasites, some of them being recognized therapeutic targets and thus the potential use of drugs with proven efficacy in the treatment of cancer for treating parasitic diseases and vice versa, opening new avenues to the one health approach.

Acknowledgements

PN gratefully acknowledges support provided by Fundación La Caixa (LCF/PR/PR13/11080005) and Fundación Caja Navarra, Gobierno Navarra Salud (12/2017), Fundación Roviralta, Ubesol, Government of Navarre, Laser Ebro and Inversores Garcilaso de la Vega S.L.

Financial support

This study was supported by the National Institute for Medical Research Development (NIMAD), Tehran, Iran, grant number 971405.

Conflict of interest

The authors declare there are no conflicts of interest.

Ethical standards

Not applicable.

References

Abdeen, S, Salim, N, Mammadova, N, Summers, CM, Goldsmith-Pestana, K, McMahon-Pratt, D, Schultz, PG, Horwich, AL, Chapman, E and Johnson, SM (2016) Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness. Bioorganic & Medicinal Chemistry Letters 26, 52475253.CrossRefGoogle ScholarPubMed
Achour, YB, Chenik, M, Louzir, H and Dellagi, K (2002) Identification of a disulfide isomerase protein of Leishmania major as a putative virulence factor. Infection and Immunity 70, 35763585.CrossRefGoogle ScholarPubMed
Afrin, F, Khan, I and Hemeg, HA (2019) Leishmania-host interactions-an epigenetic paradigm. Frontiers in Immunology 10, 492.10.3389/fimmu.2019.00492CrossRefGoogle ScholarPubMed
Al-Kamel, MAN (2017) Leishmaniasis and malignancy: a review and perspective. Clinical Skin Cancer 2, 5458.CrossRefGoogle Scholar
Amit, A, Dikhit, MR, Singh, AK, Kumar, V, Suman, SS, Singh, A, Kumar, A, Thakur, AK, Das, VR and Das, P (2017) Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice. Molecular Immunology 82, 104113.CrossRefGoogle ScholarPubMed
Amtmann, E and Sauer, G (1990) Tumor necrosis factor induces necrosis of human carcinoma xenografts in the presence of tricyclodecan-9-yl-xanthogenate and lauric acid. International Journal of Cancer 45, 11131118.CrossRefGoogle ScholarPubMed
An, X, Xu, F, Luo, R, Zheng, Q, Lu, J, Yang, Y, Qin, T, Yuan, Z, Shi, Y and Jiang, W (2018) The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. BMC Cancer 18, 110.CrossRefGoogle ScholarPubMed
Antony, S, Kohlhagen, G, Agama, K, Jayaraman, M, Cao, S, Durrani, FA, Rustum, YM, Cushman, M and Pommier, Y (2005) Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Molecular Pharmacology 67, 523530.10.1124/mol.104.003889CrossRefGoogle Scholar
Arab, S, Motamedi, M and Hadjati, J (2019) Effects of dendritic cell vaccine activated with components of Lieshmania major on tumor specific response. Iranian Journal of Immunology 16, 268277.Google ScholarPubMed
Arnér, ES (2017) Targeting the selenoprotein thioredoxin reductase 1 for anticancer therapy. Advances in Cancer Research 136, 139151.CrossRefGoogle ScholarPubMed
Azevedo, A, Toledo, JS, Defina, T, Pedrosa, AL and Cruz, AK (2015) Leishmania major phosphoglycerate kinase transcript and protein stability contributes to differences in isoform expression levels. Experimental Parasitology 159, 222226.10.1016/j.exppara.2015.09.008CrossRefGoogle ScholarPubMed
Balaña-Fouce, R, Prada, CF, Requena, JM, Cushman, M, Pommier, Y, Álvarez-Velilla, R, Escudero-Martínez, JM, Calvo-Álvarez, E, Pérez-Pertejo, Y and Reguera, RM (2012) Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 56, 52645270.CrossRefGoogle ScholarPubMed
Banerjee, B, Roy, A, Sen, N and Majumder, HK (2010) A tyrosyl DNA phosphodiesterase 1 from kinetoplastid parasite Leishmania donovani (LdTdp1) capable of removing topo I-DNA covalent complexes. Molecular Microbiology 78, 119137.Google ScholarPubMed
Batista, FA, Ramos, SL, Tassone, G, Leitão, A, Montanari, CA, Botta, M, Mori, M and Borges, JC (2020) Discovery of small molecule inhibitors of Leishmania braziliensis HSP90 chaperone. Journal of Enzyme Inhibition and Medicinal Chemistry 35, 639649.CrossRefGoogle ScholarPubMed
Bayrhuber, M, Meins, T, Habeck, M, Becker, S, Giller, K, Villinger, S, Vonrhein, C, Griesinger, C, Zweckstetter, M and Zeth, K (2008) Structure of the human voltage-dependent anion channel. Proceedings of the National Academy of Sciences 105, 1537015375.10.1073/pnas.0808115105CrossRefGoogle ScholarPubMed
Ben Khalaf, N, Muylder, G, Louzir, H, McKerrow, J and Chenik, M (2012) Leishmania major protein disulfide isomerase as a drug target. Parasitology Research 110, 19111917.CrossRefGoogle ScholarPubMed
Bernard-Marty, C, Treilleux, I, Dumontet, C, Cardoso, F, Fellous, A, Gancberg, D, Bissery, MC, Paesmans, M, Larsimont, D and Piccart, MJ (2002) Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clinical Breast Cancer 3, 341345.CrossRefGoogle ScholarPubMed
Berney, D, Shamash, J, Gaffney, J, Jordan, S and Oliver, R (2002) DNA topoisomerase I and II expression in drug resistantgerm cell tumours. British Journal of Cancer 87, 624629.CrossRefGoogle ScholarPubMed
Biyani, N, Singh, AK, Mandal, S, Chawla, B and Madhubala, R (2011) Differential expression of proteins in antimony-susceptible and-resistant isolates of Leishmania donovani. Molecular and Biochemical Parasitology 179, 9199.CrossRefGoogle ScholarPubMed
Blagosklonny, MV (2013) Immunosuppressants in cancer prevention and therapy. Oncoimmunology 2, e26961.CrossRefGoogle Scholar
Blattner, J, Swinkels, B, Dörsam, H, Prospero, T, Subramani, S and Clayton, C (1992) Glycosome assembly in trypanosomes: variations in the acceptable degeneracy of a COOH-terminal microbody targeting signal. The Journal of Cell Biology 119, 11291136.CrossRefGoogle ScholarPubMed
Blattner, J, Helfert, S, Michels, P and Clayton, C (1998) Compartmentation of phosphoglycerate kinase in Trypanosoma brucei plays a critical role in parasite energy metabolism. Proceedings of the National Academy of Sciences 95, 1159611600.CrossRefGoogle Scholar
Bleasdale, JE, Thakur, NR, Gremban, RS, Bundy, GL, Fitzpatrick, FA, Smith, RJ and Bunting, S (1990) Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. Journal of Pharmacology and Experimental Therapeutics 255, 756768.Google ScholarPubMed
Bordon, ML, Laurenti, MD, Ribeiro, SP, Toyama, MH, Toyama, D and Passero, LFD (2018) Effect of phospholipase A 2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis. Journal of Venomous Animals and Toxins Including Tropical Diseases 24, 18.CrossRefGoogle Scholar
Brandau, S, Dresel, A and Clos, J (1995) High constitutive levels of heat-shock proteins in human-pathogenic parasites of the genus Leishmania. Biochemical Journal 310, 225232.CrossRefGoogle ScholarPubMed
Breiser, A, Kim, DJ, Fleer, E, Damenz, W, Drube, A, Berger, M, Nagel, G, Eibl, H and Unger, C (1987) Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 22, 925926.CrossRefGoogle ScholarPubMed
Bringaud, F, Peris, M, Zen, KH and Simpson, L (1995) Characterization of two nuclear-encoded protein components of mitochondrial ribonucleoprotein complexes from Leishmania tarentolae. Molecular and Biochemical Parasitology 71, 6579.CrossRefGoogle ScholarPubMed
Brocker, C, Lassen, N, Estey, T, Pappa, A, Cantore, M, Orlova, VV, Chavakis, T, Kavanagh, KL, Oppermann, U and Vasiliou, V (2010) Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. Journal of Biological Chemistry 285, 1845218463.CrossRefGoogle ScholarPubMed
Cadoret, A, Ovejero, C, Terris, B, Souil, E, Levy, L, Lamers, WH, Kitajewski, J, Kahn, A and Perret, C (2002) New targets of β-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21, 82938301.CrossRefGoogle ScholarPubMed
Cai, S, Sun, PH, Resaul, J, Shi, L, Jiang, A, Satherley, LK, Davies, EL, Ruge, F, Douglas-Jones, A and Jiang, WG (2017) Expression of phospholipase C isozymes in human breast cancer and their clinical significance. Oncology Reports 37, 17071715.CrossRefGoogle ScholarPubMed
Cai, H, Liu, G, Zhong, J, Zheng, K, Xiao, H, Li, C, Song, X, Li, Y, Xu, C and Wu, H (2020) Immune checkpoints in viral infections. Viruses 12, 1051.CrossRefGoogle ScholarPubMed
Caner, A, Sadıqova, A, Erdoğan, A, Namlıses, D, Nalbantsoy, A, Oltulu, F, Toz, S, Yiğittürk, G, Ozkök, E and Gunduz, C (2020) Targeting of antitumor immune responses with live-attenuated Leishmania strains in breast cancer model. Breast Cancer (Tokyo, Japan) 27, 10821095.CrossRefGoogle ScholarPubMed
Cappello, F, Marino Gammazza, A, Palumbo Piccionello, A, Campanella, C, Pace, A, Conway de Macario, E and Macario, AJ (2014) HSP60 chaperonopathies and chaperonotherapy: targets and agents. Expert Opinion on Therapeutic Targets 18, 185208.CrossRefGoogle ScholarPubMed
Carballeira, NM (2013) Recent developments in the antiprotozoal and anticancer activities of the 2-alkynoic fatty acids. Chemistry and Physics of Lipids 172, 5866.CrossRefGoogle ScholarPubMed
Carballeira, NM, Cartagena, MM, Prada, CF, Rubio, CF and Balaña-Fouce, R (2009) Total synthesis and antileishmanial activity of the natural occurring acetylenic fatty acids 6-heptadecynoic acid and 6-icosynoic acid. Lipids 44, 953961.CrossRefGoogle ScholarPubMed
Carballeira, NM, Montano, N, Cintrón, GA, Márquez, C, Rubio, CF, Prada, CF and Balaña-Fouce, R (2011) First total synthesis and antileishmanial activity of (Z)-16-methyl-11-heptadecenoic acid, a new marine fatty acid from the sponge Dragmaxia undata. Chemistry and Physics of Lipids 164, 113117.CrossRefGoogle Scholar
Carballeira, NM, Cartagena, M, Li, F, Chen, Z, Prada, CF, Calvo-Alvarez, E, Reguera, RM and Balaña-Fouce, R (2012 a) First total synthesis of the (±)-2-methoxy-6-heptadecynoic acid and related 2-methoxylated analogs as effective inhibitors of the Leishmania topoisomerase IB enzyme. Pure and Applied Chemistry 84, 18671875.CrossRefGoogle ScholarPubMed
Carballeira, NM, Cartagena, M, Sanabria, D, Tasdemir, D, Prada, CF, Reguera, RM and Balaña-Fouce, R (2012 b) 2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani. Bioorganic & Medicinal Chemistry Letters 22, 61856189.CrossRefGoogle ScholarPubMed
Carballeira, NM, Montano, N, Alvarez-Velilla, R, Prada, CF, Reguera, RM and Balaña-Fouce, R (2013) Synthesis of marine α-methoxylated fatty acid analogs that effectively inhibit the topoisomerase IB from Leishmania donovani with a mechanism different from that of camptothecin. Marine Drugs 11, 36613675.CrossRefGoogle ScholarPubMed
Carballeira, NM, Montano, N, Amador, LA, Rodríguez, AD, Golovko, MY, Golovko, SA, Reguera, RM, Álvarez-Velilla, R and Balaña-Fouce, R (2016) Novel very long-chain α-methoxylated Δ5, 9 fatty acids from the sponge Asteropus niger are effective inhibitors of topoisomerases IB. Lipids 51, 245256.CrossRefGoogle ScholarPubMed
Carballeira, NM, Morales-Guzman, C, Alvarez-Benedicto, E, Torres-Martinez, Z, Delgado, Y, Griebenow, KH, Tinoco, AD, Reguera, RM, Perez-Pertejo, Y and Carbajo-Andres, R (2018) First total synthesis of ω-phenyl Δ6 fatty acids and their leishmanicidal and anticancer properties. Current Topics in Medicinal Chemistry 18, 418427.10.2174/1568026618666180516125056CrossRefGoogle ScholarPubMed
Carrillo-Larco, RM, Acevedo-Rodriguez, JG, Altez-Fernandez, C, Ortiz-Acha, K and Ugarte-Gil, C (2019) Is there an association between cutaneous leishmaniasis and skin cancer? A systematic review. Wellcome Open Research 4, 110.CrossRefGoogle ScholarPubMed
Cecchetti, S, Bortolomai, I, Ferri, R, Mercurio, L, Canevari, S, Podo, F, Miotti, S and Iorio, E (2015) Inhibition of phosphatidylcholine-specific phospholipase C interferes with proliferation and survival of tumor initiating cells in squamous cell carcinoma. PLoS One 10, e0136120.CrossRefGoogle ScholarPubMed
Celeste, B, Angel, SO, Castro, L, Gidlund, M and Goto, H (2004) Leishmania infantum heat shock protein 83 for the serodiagnosis of tegumentary leishmaniasis. Brazilian Journal of Medical and Biological Research 37, 15911593.CrossRefGoogle ScholarPubMed
Cencini, E, Lazzi, S and Fabbri, A (2015) Atypical clinical presentation of visceral leishmaniasis in a patient with non-Hodgkin lymphoma. European Journal of Haematology 2, 186186.CrossRefGoogle Scholar
Chaiwatanasirikul, K and Sala, A (2011) The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. Cell Death & Disease 2, e219e219.CrossRefGoogle ScholarPubMed
Chakraborty, S, Srivastava, A, Jha, MK, Nair, A, Pandey, SP, Srivastava, N, Kumari, S, Singh, S, Krishnasastry, MW and Saha, B (2015) Inhibition of CD40-induced N-Ras activation reduces Leishmania major infection. The Journal of Immunology 194, 38523860.CrossRefGoogle ScholarPubMed
Chang, CL, Hsu, YT, Wu, CC, Yang, YC, Wang, C, Wu, TC and Hung, CF (2012) Immune mechanism of the antitumor effects generated by bortezomib. The Journal of Immunology 189, 32093220.CrossRefGoogle ScholarPubMed
Chavali, AK, Whittemore, JD, Eddy, JA, Williams, KT and Papin, JA (2008) Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major. Molecular Systems Biology 4, 177.CrossRefGoogle ScholarPubMed
Cheeseman, K and Weitzman, J (2017) Comment et pourquoi un parasite peut-il être ‘transformant’? Apports d'agents de zoonoses exotiques, Theileria spp., à l’étude du cancer. Bulletin de la Société de Pathologie Exotique 110, 5560.CrossRefGoogle Scholar
Chen, Y and Zhou, X (2020) Research progress of mTOR inhibitors. European Journal of Medicinal Chemistry 208, 112820.CrossRefGoogle ScholarPubMed
Chowdhury, S, Mukherjee, T, Sengupta, S, Chowdhury, SR, Mukhopadhyay, S and Majumder, HK (2011) Novel betulin derivatives as antileishmanial agents with mode of action targeting type IB DNA topoisomerase. Molecular Pharmacology 80, 694703.CrossRefGoogle ScholarPubMed
Chowdhury, SR, Godinho, JLP, Vinayagam, J, Zuma, AA, Silva, STDM, Jaisankar, P, Rodrigues, JCF, De Souza, W and Majumder, HK (2018) Isobenzofuranone derivative JVPH3, an inhibitor of L. donovani topoisomerase II, disrupts mitochondrial architecture in trypanosomatid parasites. Scientific Reports 8, 111.CrossRefGoogle ScholarPubMed
Clark, DW and Palle, K (2016) Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Annals of Translational Medicine 4, 518.10.21037/atm.2016.11.82CrossRefGoogle ScholarPubMed
Claudio, U, Alessandro, O, Luca, C, Jacopo, V and Katia, F (2019) Visceral leishmaniasis in a patient with lung tumour: a case report. Tropical Doctor 49, 147149.CrossRefGoogle Scholar
Colnot, S, Decaens, T, Niwa-Kawakita, M, Godard, C, Hamard, G, Kahn, A, Giovannini, M and Perret, C (2004) Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinomas. Proceedings of the National Academy of Sciences 101, 1721617221.CrossRefGoogle ScholarPubMed
Costa, CA, Lopes, RM, Ferraz, LS, Esteves, GN, Di Iorio, JF, Souza, AA, de Oliveira, IM, Manarin, F, Judice, WA and Stefani, HA (2020) Cytotoxicity of 4-substituted quinoline derivatives: anticancer and antileishmanial potential. Bioorganic & Medicinal Chemistry 28, 115511.CrossRefGoogle ScholarPubMed
Cowell, AN and Winzeler, EA (2019) Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections. Genome Medicine 11, 654663.CrossRefGoogle ScholarPubMed
Dacher, M, Tachiwana, H, Horikoshi, N, Kujirai, T, Taguchi, H, Kimura, H and Kurumizaka, H (2019) Incorporation and influence of Leishmania histone H3 in chromatin. Nucleic Acids Research 47, 1163711648.Google ScholarPubMed
Daly, EB, Wind, T, Jiang, X-M, Sun, L and Hogg, PJ (2004) Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1691, 1722.CrossRefGoogle ScholarPubMed
Danesh-Bahreini, MA, Shokri, J, Samiei, A, Kamali-Sarvestani, E, Barzegar-Jalali, M and Mohammadi-Samani, S (2011) Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. International Journal of Nanomedicine 6, 835842.Google ScholarPubMed
Da Silva, M, Silva-Jardim, I and Thiemann, O (2014) Biological implications of selenium and its role in trypanosomiasis treatment. Current Medicinal Chemistry 21, 17721780.CrossRefGoogle ScholarPubMed
Dean, RA, Fam, HK, An, J, Choi, K, Shimizu, Y, Jones, SJ, Boerkoel, CF, Interthal, H and Pfeifer, TA (2014) Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays. Journal of Biomolecular Screening 19, 13721382.CrossRefGoogle ScholarPubMed
De Martel, C, Ferlay, J, Franceschi, S, Vignat, J, Bray, F, Forman, D and Plummer, M (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology 13, 607615.CrossRefGoogle ScholarPubMed
Den Boer, M, Argaw, D, Jannin, J and Alvar, J (2011) Leishmaniasis impact and treatment access. Clinical Microbiology and Infection 17, 14711477.CrossRefGoogle ScholarPubMed
Depowski, PL, Rosenthal, SI, Brien, TP, Stylos, S, Johnson, RL and Ross, JS (2000) Topoisomerase IIα expression in breast cancer: correlation with outcome variables. Modern Pathology 13, 542547.CrossRefGoogle ScholarPubMed
Desmetz, C, Bibeau, F, Boissiere, F, Bellet, V, Rouanet, P, Maudelonde, T, Mangé, A and Solassol, J (2008) Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. Journal of Proteome Research 7, 38303837.CrossRefGoogle ScholarPubMed
Dillehay, KL, Lu, S and Dong, Z (2014) Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer. Molecular Cancer Therapeutics 13, 28172826.CrossRefGoogle ScholarPubMed
Dinavahi, SS, Gowda, R, Bazewicz, CG, Battu, MB, Lin, JM, Chitren, RJ, Pandey, MK, Amin, S, Robertson, GP and Gowda, K (2020) Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents. European Journal of Medicinal Chemistry 187, 111962.CrossRefGoogle ScholarPubMed
Dorlo, TP, Eggelte, TA, de Vries, PJ and Beijnen, JH (2012) Characterization and identification of suspected counterfeit miltefosine capsules. The Analyst 137, 12651274.CrossRefGoogle ScholarPubMed
dos Santos Nogueira, F, Avino, VC, Galvis-Ovallos, F, Pereira-Chioccola, VL, Moreira, MAB, Romariz, APPL, Molla, LM and Menz, I (2019) Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. Parasites & Vectors 12, 79.CrossRefGoogle ScholarPubMed
Doyle, LA (1994) Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemotherapy and Pharmacology 34, S32S40.CrossRefGoogle ScholarPubMed
Du, J, Li, B, Fang, Y, Liu, Y, Wang, Y, Li, J, Zhou, W and Wang, X (2015) Overexpression of class III β-tubulin, Sox2, and nuclear survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. BMC Cancer 15, 536.CrossRefGoogle ScholarPubMed
Dubey, A, Prajapati, K, Swamy, M and Pachauri, V (2015) Heat shock proteins: a therapeutic target worth to consider. Veterinary World 8, 4651.CrossRefGoogle ScholarPubMed
Dumay, A, Rincheval, V, Trotot, P, Mignotte, B and Vayssière, J-L (2006) The superoxide dismutase inhibitor diethyldithiocarbamate has antagonistic effects on apoptosis by triggering both cytochrome c release and caspase inhibition. Free Radical Biology and Medicine 40, 13771390.CrossRefGoogle ScholarPubMed
Escudero-Martínez, JM, Pérez-Pertejo, Y, Reguera, RM, Castro, MA, Rojo, MV, Santiago, C, Abad, A, García, PA, López-Pérez, JL and San Feliciano, A (2017) Antileishmanial activity and tubulin polymerization inhibition of podophyllotoxin derivatives on Leishmania infantum. International Journal for Parasitology: Drugs and Drug Resistance 7, 272285.Google ScholarPubMed
Espinosa, AV, Costa, D, Tunes, LG, Monte-Neto, R, Grazul, RM, de Almeida, MV and Silva, H (2020) Anticancer and antileishmanial in vitro activity of gold(I) complexes with 1, 3, 4-oxadiazole-2 (3H)-thione ligands derived from δ-D-gluconolactone. Chemical Biology & Drug Design 97, 4150. doi: 10.1111/cbdd.13757CrossRefGoogle ScholarPubMed
Ezra, N, Ochoa, MT and Craft, N (2010) Human immunodeficiency virus and leishmaniasis. Journal of Global Infectious Diseases 2, 248257.Google ScholarPubMed
Feng, X, Feistel, T, Buffalo, C, McCormack, A, Kruvand, E, Rodriguez-Contreras, D, Akopyants, NS, Umasankar, P, David, L and Jardim, A (2011) Remodeling of protein and mRNA expression in Leishmania mexicana induced by deletion of glucose transporter genes. Molecular and Biochemical Parasitology 175, 3948.CrossRefGoogle ScholarPubMed
Fernández-Rubio, C, Campbell, D, Vacas, A, Ibañez, E, Moreno, E, Espuelas, S, Calvo, A, Palop, JA, Plano, D and Sanmartin, C (2015) Leishmanicidal activities of novel methylseleno-imidocarbamates. Antimicrobial Agents and Chemotherapy 59, 57055713.CrossRefGoogle ScholarPubMed
Fernández-Rubio, C, Larrea, E, Guerrero, JP, Herrero, ES, Gamboa, I, Berrio, C, Plano, D, Amin, S, Sharma, AK and Nguewa, PA (2019) Leishmanicidal activity of isoselenocyanate derivatives. Antimicrobial Agents and Chemotherapy 63, 0090400918.CrossRefGoogle ScholarPubMed
Ferro, S, Palmieri, C, Cavicchioli, L, Zan, GD, Aresu, L and Benali, S (2013) Leishmania amastigotes in neoplastic cells of 3 nonhistiocytic canine tumors. Veterinary Pathology 50, 749752.CrossRefGoogle ScholarPubMed
Fuertes, MA, Alonso, C and Pérez, JM (2003) Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chemical Reviews 103, 645662.CrossRefGoogle ScholarPubMed
Ghosh, JC, Siegelin, MD, Dohi, T and Altieri, DC (2010) Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Research 70, 89888993.CrossRefGoogle ScholarPubMed
Giaccone, G, van Ark-Otte, J, Scagliotti, G, Capranico, G, van der Valk, P, Rubio, G, Dalesio, O, Lopez, R, Zunino, F and Walboomers, J (1995) Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1264, 337346.CrossRefGoogle ScholarPubMed
Glasauer, A, Sena, LA, Diebold, LP, Mazar, AP and Chandel, NS (2014) Targeting SOD1 reduces experimental non-small-cell lung cancer. The Journal of Clinical Investigation 124, 117128.CrossRefGoogle ScholarPubMed
Gouveris, P, Lazaris, A, Papathomas, T, Nonni, A, Kyriakou, V, Delladetsima, J, Patsouris, E and Tsavaris, N (2007) Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology 133, 10111015.CrossRefGoogle ScholarPubMed
Gupta, SK, Sisodia, BS, Sinha, S, Hajela, K, Naik, S, Shasany, AK and Dube, A (2007) Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 7, 816823.CrossRefGoogle ScholarPubMed
Gutiérrez-Corbo, C, Álvarez-Velilla, R, Reguera, RM, García-Estrada, C, Cushman, M, Balaña-Fouce, R and Pérez-Pertejo, Y (2019) Topoisomerase IB poisons induce histone H2A phosphorylation as a response to DNA damage in Leishmania infantum. International Journal for Parasitology: Drugs and Drug Resistance 11, 3948.Google ScholarPubMed
Hart, DT and Opperdoes, FR (1984) The occurrence of glycosomes (microbodies) in the promastigote stage of four major Leishmania species. Molecular and Biochemical Parasitology 13, 159172.CrossRefGoogle ScholarPubMed
He, Y, Luo, Y, Zhang, D, Wang, X, Zhang, P, Li, H, Ejaz, S and Liang, S (2019) PGK1-mediated cancer progression and drug resistance. American Journal of Cancer Research 9, 22802302.Google Scholar
Hevener, K, Verstak, TA, Lutat, KE, Riggsbee, DL and Mooney, JW (2018) Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharmaceutica Sinica B 8, 844861.CrossRefGoogle ScholarPubMed
Hjerpe, E, Egyhazi, S, Carlson, J, Stolt, MF, Schedvins, K, Johansson, H, Shoshan, M and Avall-Lundqvist, E (2013) HSP60 Predicts survival in advanced serous ovarian cancer. International Journal of Gynecologic Cancer 23, 448455.CrossRefGoogle ScholarPubMed
Ho, MY, Tang, SJ, Ng, WV, Yang, W, Leu, SJJ, Lin, YC, Feng, CK, Sung, JS and Sun, KH (2010) Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression. Cancer Science 101, 24112416.CrossRefGoogle ScholarPubMed
Huang, W, Barrett, M, Hajicek, N, Hicks, S, Harden, TK, Sondek, J and Zhang, Q (2013) Small molecule inhibitors of phospholipase C from a novel high-throughput screen. Journal of Biological Chemistry 288, 58405848.CrossRefGoogle ScholarPubMed
Hwang, JE, Hong, JY, Kim, K, Kim, SH, Choi, WY, Kim, MJ, Jung, SH, Shim, HJ, Bae, WK and Hwang, EC (2013) Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. BMC Cancer 13, 431.CrossRefGoogle ScholarPubMed
Ibanez, E, Agliano, A, Prior, C, Nguewa, P, Redrado, M, Gonzalez-Zubeldia, I, Plano, D, Palop, JA, Sanmartin, C and Calvo, A (2012) The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity. Current Medicinal Chemistry 19, 30313043.CrossRefGoogle ScholarPubMed
Ilari, A, Baiocco, P, Messori, L, Fiorillo, A, Boffi, A, Gramiccia, M, Di Muccio, T and Colotti, G (2012) A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids 42, 803811.CrossRefGoogle ScholarPubMed
Ilari, A, Fiorillo, A, Baiocco, P, Poser, E, Angiulli, G and Colotti, G (2015) Targeting polyamine metabolism for finding new drugs against leishmaniasis: a review. Mini Reviews in Medicinal Chemistry 15, 243252.CrossRefGoogle ScholarPubMed
Iorio, E, Ricci, A, Bagnoli, M, Pisanu, ME, Castellano, G, Di Vito, M, Venturini, E, Glunde, K, Bhujwalla, ZM and Mezzanzanica, D (2010) Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Research 70, 21262135.CrossRefGoogle ScholarPubMed
Iribar, M, Tosi, L and Cruz, A (2003) A processed short transcript of Leishmania, ODD1. Molecular and Biochemical Parasitology 127, 205208.CrossRefGoogle Scholar
Jaiswal, AK, Khare, P, Joshi, S, Kushawaha, PK, Sundar, S and Dube, A (2014) Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. PLoS One 9, e108556.CrossRefGoogle ScholarPubMed
Januchowski, R, Wojtowicz, K and Zabel, M (2013) The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomedicine & Pharmacotherapy 67, 669680.CrossRefGoogle Scholar
Jayanarayan, K and Dey, C (2003) Overexpression and increased DNA topoisomerase II-like enzyme activity in arsenite resistant Leishmania donovani. Microbiological Research 158, 5558.CrossRefGoogle ScholarPubMed
Jayanarayan, K and Dey, CS (2004) Altered expression, polymerisation and cellular distribution of α-/β-tubulins and apoptosis-like cell death in arsenite resistant Leishmania donovani promastigotes. International Journal for Parasitology 34, 915925.CrossRefGoogle ScholarPubMed
Jiang, H, Yu, X-M, Zhou, X-M, Wang, X-H and Su, D (2013) Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer. Experimental and Therapeutic Medicine 5, 15061510.CrossRefGoogle ScholarPubMed
Jiang, H, Zhang, WJ, Li, PH, Wang, J, Dong, CZ, Zhang, K, Chen, HX and Du, ZY (2018) Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors. Bioorganic & Medicinal Chemistry Letters 28, 13201323.CrossRefGoogle ScholarPubMed
Jiménez, R, Pequerul, R, Amor, A, Lorenzo, J, Metwally, K, Avilés, FX, Parés, X and Farrés, J (2019) Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: kinetic characterization and effect on human cancer cells. Chemico-Biological Interactions 306, 123130.CrossRefGoogle ScholarPubMed
Jordan, M (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Current Medicinal Chemistry-Anti-Cancer Agents 2, 117.CrossRefGoogle ScholarPubMed
Jordan, MA and Wilson, L (2004) Microtubules as a target for anticancer drugs. Nature Reviews Cancer 4, 253265.CrossRefGoogle ScholarPubMed
Kahlos, K, Soini, Y, Saily, M, Koistinen, P, Kakko, S, Paakko, P, Holmgren, A and Kinnula, VL (2001) Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. International Journal of Cancer 95, 198204.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Kale, VP, Amin, SG and Pandey, MK (2015) Targeting ion channels for cancer therapy by repurposing the approved drugs. Biochimica et Biophysica Acta (BBA)-Biomembranes 1848, 27472755.CrossRefGoogle ScholarPubMed
Kang, SM, Kim, SJ, Kim, JH, Lee, W, Kim, GW, Lee, KH, Choi, KY and Oh, JW (2009) Interaction of hepatitis C virus core protein with HSP60 triggers the production of reactive oxygen species and enhances TNF-α-mediated apoptosis. Cancer Letters 279, 230237.CrossRefGoogle ScholarPubMed
Kang, JH, Lee, SH, Hong, D, Lee, JS, Ahn, HS, Ahn, JH, Seong, TW, Lee, CH, Jang, H and Hong, KM (2016) Aldehyde dehydrogenase is used by cancer cells for energy metabolism. Experimental & Molecular Medicine 48, e272e272.CrossRefGoogle ScholarPubMed
Karelia, DN, Sk, UH, Singh, P, Gowda, AP, Pandey, MK, Ramisetti, SR, Amin, S and Sharma, AK (2017) Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual topoisomerase-IIα and Akt pathway inhibitor, and evaluation of its anti-melanoma activity. European Journal of Medicinal Chemistry 135, 282295.CrossRefGoogle ScholarPubMed
Kashif, M, Manna P, P, Akhter, Y, Alaidarous, M and Rub, A (2017) Screening of novel inhibitors against Leishmania donovani calcium ion channel to fight leishmaniasis. Infectious Disorders-Drug Targets 17, 120129.CrossRefGoogle ScholarPubMed
Kazemi-Rad, E, Mohebali, M, Khadem-Erfan, MB, Saffari, M, Raoofian, R, Hajjaran, H, Hadighi, R, Khamesipour, A, Rezaie, S and Abedkhojasteh, H (2013) Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach. Experimental Parasitology 135, 344349.CrossRefGoogle ScholarPubMed
Keithly, JS and Fairlamb, AH (1989) Inhibition of Leishmania species by α-difluoromethylornithine. Leishmaniasis 171, 749756.CrossRefGoogle Scholar
Keithly, JS, Langreth, SG, Buttle, KF and Mannella, CA (2005) Electron tomographic and ultrastructural analysis of the Cryptosporidium parvum relict mitochondrion, its associated membranes, and organelles. Journal of Eukaryotic Microbiology 52, 132140.CrossRefGoogle ScholarPubMed
Khan, S, Ince-Dunn, G, Suomalainen, A and Elo, LL (2020) Integrative omics approaches provide biological and clinical insights: examples from mitochondrial diseases. The Journal of Clinical Investigation 130, 2028.CrossRefGoogle ScholarPubMed
Khomenko, TM, Zakharenko, AL, Chepanova, AA, Ilina, ES, Zakharova, OD, Kaledin, VI, Nikolin, VP, Popova, NA, Korchagina, DV and Reynisson, J (2020) Promising new inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 4-arylcoumarin and monoterpenoid moieties as components of complex antitumor therapy. International Journal of Molecular Sciences 21, 126.CrossRefGoogle Scholar
Koppaka, V, Thompson, DC, Chen, Y, Ellermann, M, Nicolaou, KC, Juvonen, RO, Petersen, D, Deitrich, RA, Hurley, TD and Vasiliou, V (2012) Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacological Reviews 64, 520539.CrossRefGoogle ScholarPubMed
Kopterides, P, Mourtzoukou, E, Skopelitis, E, Tsavaris, N and Falagas, M (2007) Aspects of the association between leishmaniasis and malignant disorders. Transactions of the Royal Society of Tropical Medicine and Hygiene 101, 11811189.CrossRefGoogle ScholarPubMed
Kumar, R, Daga, MK, Kamble, NL, Sothwal, A, Singh, T, Nayak, HK and Raizada, N (2011) Rare association of visceral leishmaniasis with hodgkin's disease: a case report. Infectious Agents and Cancer 6, 17.CrossRefGoogle ScholarPubMed
Kumar, A, Chowdhury, SR, Jatte, KK, Chakrabarti, T, Majumder, HK, Jha, T and Mukhopadhyay, S (2015) Anthocephaline, a new indole alkaloid and cadambine, a potent inhibitor of DNA topoisomerase IB of Leishmania donovani (LdTOP1LS), isolated from Anthocephalus cadamba. Natural Product Communications 10, 297299.CrossRefGoogle Scholar
Kumar, A, Chowdhury, SR, Sarkar, T, Chakrabarti, T, Majumder, HK, Jha, T and Mukhopadhyay, S (2016) A new bisbenzylisoquinoline alkaloid isolated from Thalictrum foliolosum, as a potent inhibitor of DNA topoisomerase IB of Leishmania donovani. Fitoterapia 109, 2530.CrossRefGoogle ScholarPubMed
Kumar, R, Chauhan, SB, Ng, SS, Sundar, S and Engwerda, CR (2017) Immune checkpoint targets for host-directed therapy to prevent and treat leishmaniasis. Frontiers in Immunology 8, 1492.CrossRefGoogle ScholarPubMed
Kumar, A, Das, S, Mandal, A, Verma, S, Abhishek, K, Kumar, A, Kumar, V, Ghosh, AK and Das, P (2018) Leishmania infection activates host mTOR for its survival by M2 macrophage polarization. Parasite Immunology 40, e12586.CrossRefGoogle ScholarPubMed
Kumar, R, Bunn, PT, Singh, SS, Ng, SS, de Oca, MM, Rivera, FDL, Chauhan, SB, Singh, N, Faleiro, RJ and Edwards, CL (2020) Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral leishmaniasis. Cell Reports 30, 25122525.CrossRefGoogle ScholarPubMed
Kümler, I, Balslev, E, Stenvang, J, Brunner, N and Nielsen, D (2015) A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2-negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. BMC Cancer 15, 78.CrossRefGoogle ScholarPubMed
Lattanzio, R, Piantelli, M and Falasca, M (2013) Role of phospholipase C in cell invasion and metastasis. Advances in Biological Regulation 53, 309318.CrossRefGoogle ScholarPubMed
Lawen, A, Ly, JD, Lane, DJ, Zarschler, K, Messina, A and De Pinto, V (2005) Voltage-dependent anion-selective channel 1 (VDAC1)-a mitochondrial protein, rediscovered as a novel enzyme in the plasma membrane. The International Journal of Biochemistry & Cell Biology 37, 277282.CrossRefGoogle ScholarPubMed
Leanza, L, Manago, A, Zoratti, M, Gulbins, E and Szabo, I (2016) Pharmacological targeting of ion channels for cancer therapy: in vivo evidences. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1863, 13851397.CrossRefGoogle ScholarPubMed
Lee, E (2017) Emerging roles of protein disulfide isomerase in cancer. BMB Reports 50, 401.CrossRefGoogle ScholarPubMed
Li, L, Jiang, S, Li, X, Liu, Y, Su, J and Chen, J (2018 a) Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site. European Journal of Medicinal Chemistry 151, 482494.CrossRefGoogle ScholarPubMed
Li, PH, Jiang, H, Zhang, WJ, Li, YL, Zhao, MC, Zhou, W, Zhang, LY, Tang, YD, Dong, CZ and Huang, ZS (2018 b) Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers. European Journal of Medicinal Chemistry 145, 498510.CrossRefGoogle ScholarPubMed
Liao, JB (2006) Cancer issue: viruses and human cancer. The Yale Journal of Biology and Medicine 79, 115122.Google Scholar
Liao, H, Jin, Y, Yu, J and Jiang, N (2018) Concomitant T-cell prolymphocytic leukemia and visceral leishmaniasis: a case report. Medicine 97, e12410.CrossRefGoogle ScholarPubMed
Liberio, MS, Sadowski, MC, Davis, RA, Rockstroh, A, Vasireddy, R, Lehman, ML and Nelson, CC (2015) The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells. Oncotarget 6, 43944.CrossRefGoogle ScholarPubMed
Lincoln, DT, Ali, EE, Tonissen, KF and Clarke, FM (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Research 23, 24252433.Google ScholarPubMed
Liu, C, Zhou, S, Begum, S, Sidransky, D, Westra, WH, Brock, M and Califano, JA (2007) Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 55, 303311.CrossRefGoogle ScholarPubMed
Liu, L-M, Xiong, D-D, Lin, P, Yang, H, Dang, Y-W and Chen, G (2018) DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride. International Journal of Oncology 53, 18971912.Google ScholarPubMed
Lohavanichbutr, P, Sakoda, LC, Amos, CI, Arnold, SM, Christiani, DC, Davies, MP, Field, JK, Haura, EB, Hung, RJ and Kohno, T (2017) Common TDP1 polymorphisms in relation to survival among small cell lung cancer patients: a multicenter study from the International Lung Cancer Consortium. Clinical Cancer Research 23, 75507557.CrossRefGoogle ScholarPubMed
Lu, S and Dong, Z (2019) Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells. PLoS One 14, e0223894.CrossRefGoogle ScholarPubMed
Lu, Y, Chen, J, Xiao, M, Li, W and Miller, DD (2012) An overview of tubulin inhibitors that interact with the colchicine binding site. Pharmaceutical Research 29, 29432971.CrossRefGoogle ScholarPubMed
Luis, L, Serrano, ML, Hidalgo, M and Mendoza-León, A (2013) Comparative analyses of the β-tubulin gene and molecular modeling reveal molecular insight into the colchicine resistance in kinetoplastids organisms. BioMed Research International 2013, 843748.CrossRefGoogle ScholarPubMed
Lynch, BJ, Bronstein, IB and Holden, JA (2001) Elevations of DNA topoisomerase I in invasive carcinoma of the breast. The Breast Journal 7, 176180.CrossRefGoogle ScholarPubMed
Ma, LW, Zhou, ZT, He, QB and Jiang, WW (2013) Phospholipase C-γ1 expression correlated with cancer progression of potentially malignant oral lesions. Journal of Oral Pathology & Medicine 42, 4752.CrossRefGoogle ScholarPubMed
Magalhaes, RD, Duarte, MC, Mattos, EC, Martins, VT, Lage, PS, Chavez-Fumagalli, MA, Lage, DP, Menezes-Souza, D, Regis, WC and Alves, MJM (2014) Identification of differentially expressed proteins from Leishmania amazonensis associated with the loss of virulence of the parasites. PLoS Neglected Tropical Diseases 8, e2764.CrossRefGoogle ScholarPubMed
Mamontova, E, Zakharenko, A, Zakharova, O, Dyrkheeva, N, Volcho, K, Reynisson, J, Arabshahi, H, Salakhutdinov, N and Lavrik, O (2020) Identification of novel inhibitors for the tyrosyl-DNA-phosphodiesterase 1 (Tdp1) mutant SCAN1 using virtual screening. Bioorganic & Medicinal Chemistry 28, 115234.CrossRefGoogle ScholarPubMed
Manhas, R, Gowri, VS and Madhubala, R (2016) Leishmania donovani encodes a functional selenocysteinyl-tRNA synthase. Journal of Biological Chemistry 291, 12031220.CrossRefGoogle ScholarPubMed
Marquis, J-F, Makhey, D, LaVoie, EJ and Olivier, M (2003) Effects of topoisomerases inhibitors protoberberine on Leishmania donovani growth, macrophage function, and infection. Journal of Parasitology 89, 10481052.CrossRefGoogle Scholar
Martín-Montes, A, Plano, D, Martín-Escolano, R, Alcolea, V, Díaz, M, Pérez-Silanes, S, Espuelas, S, Moreno, E, Marín, C and Gutiérrez-Sánchez, R (2017) Library of seleno-compounds as novel agents against Leishmania species. Antimicrobial Agents and Chemotherapy 61, e02546–16.CrossRefGoogle ScholarPubMed
Martínez-Flórez, A, Galizzi, M, Izquierdo, L, Bustamante, JM, Rodriguez, A, Rodriguez, F, Rodríguez-Cortés, A and Alberola, J (2020) Repurposing bioenergetic modulators against protozoan parasites responsible for tropical diseases. International Journal for Parasitology: Drugs and Drug Resistance 14, 1727.Google ScholarPubMed
Matrangolo, FS, Liarte, DB, Andrade, LC, de Melo, MF, Andrade, JM, Ferreira, RF, Santiago, AS, Pirovani, CP, Silva-Pereira, RA and Murta, SM (2013) Comparative proteomic analysis of antimony-resistant and-susceptible Leishmania braziliensis and Leishmania infantum chagasi lines. Molecular and Biochemical Parasitology 190, 6375.CrossRefGoogle ScholarPubMed
McCall, KD, Muccioli, M and Benencia, F (2020) Toll-like receptors signaling in the tumor microenvironment. Advances in Experimental Medicine and Biology 1223, 8197.CrossRefGoogle ScholarPubMed
McKoy, G, Badal, M, Prescott, Q, Lux, H and Hart, DT (1997) Characterisation of phosphoglycerate kinase genes in Leishmania major and evidence for the absence of a third closely related gene or isoenzyme. Molecular and Biochemical Parasitology 90, 169181.CrossRefGoogle ScholarPubMed
Meisenberg, C, Gilbert, DC, Chalmers, A, Haley, V, Gollins, S, Ward, SE and El-Khamisy, SF (2015) Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Molecular Cancer Therapeutics 14, 575585.CrossRefGoogle ScholarPubMed
Meng, Q, Li, BX and Xiao, X (2018) Toward developing chemical modulators of HSP60 as potential therapeutics. Frontiers in Molecular Biosciences 5, 35.CrossRefGoogle ScholarPubMed
Merritt, C, Silva, LE, Tanner, AL, Stuart, K and Pollastri, MP (2014) Kinases as druggable targets in trypanosomatid protozoan parasites. Chemical Reviews 114, 1128011304.CrossRefGoogle ScholarPubMed
Miguel, DC, Yokoyama-Yasunaka, JK, Andreoli, WK, Mortara, RA and Uliana, SR (2007) Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. Journal of Antimicrobial Chemotherapy 60, 526534.CrossRefGoogle ScholarPubMed
Miguel, DC, Yokoyama-Yasunaka, JK and Uliana, SR (2008) Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Neglected Tropical Diseases 2, e249.CrossRefGoogle ScholarPubMed
Mishra, A, Vinayagam, J, Saha, S, Chowdhury, S, Roychowdhury, S, Jaisankar, P and Majumder, HK (2014) Isobenzofuranone derivatives exhibit antileishmanial effect by inhibiting type II DNA topoisomerase and inducing host response. Pharmacology Research & Perspectives 2, e00070.CrossRefGoogle ScholarPubMed
Montecinos-Franjola, F, Chaturvedi, SK, Schuck, P and Sackett, DL (2019) All tubulins are not alike: heterodimer dissociation differs among different biological sources. Journal of Biological Chemistry 294, 1031510324.CrossRefGoogle Scholar
Morgan, RE, Ahn, S, Nzimiro, S, Fotie, J, Phelps, MA, Cotrill, J, Yakovich, AJ, Sackett, DL, Dalton, JT and Werbovetz, KA (2008) Inhibitors of tubulin assembly identified through screening a compound library. Chemical Biology & Drug Design 72, 513524.CrossRefGoogle ScholarPubMed
Morsy, TA (2013) Cutaneous leishmaniasis predisposing to human skin cancer: forty years local and regional studies. Journal of the Egyptian Society of Parasitology 43, 629648.Google ScholarPubMed
Moudy, R, Manning, TJ and Beckers, CJ (2001) The loss of cytoplasmic potassium upon host cell breakdown triggers egress of Toxoplasma gondii. Journal of Biological Chemistry 276, 4149241501.CrossRefGoogle ScholarPubMed
Moulisha, B, Kumar, GA and Kanti, HP (2010) Anti-leishmanial and anti-cancer activities of a pentacyclic triterpenoid isolated from the leaves of Terminalia arjuna Combretaceae. Tropical Journal of Pharmaceutical Research 9, 135140.CrossRefGoogle Scholar
Mozhaitsev, ES, Zakharenko, AL, Suslov, EV, Korchagina, DV, Zakharova, OD, Vasil'eva, IA, Chepanova, AA, Black, E, Patel, J and Chand, R (2019) Novel inhibitors of DNA repair enzyme TDP1 combining monoterpenoid and adamantane fragments. Anti-Cancer Agents in Medicinal Chemistry 19, 463472.CrossRefGoogle ScholarPubMed
Mrklic, I, Pogorelic, Z, Capkun, V and Tomic, S (2014) Expression of topoisomerase II-α in triple negative breast cancer. Applied Immunohistochemistry & Molecular Morphology 22, 182187.CrossRefGoogle ScholarPubMed
Mukherjee, S, Das, L, Kole, L, Karmakar, S, Datta, N and Das, PK (2004) Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. The Journal of Infectious Diseases 189, 10241034.CrossRefGoogle ScholarPubMed
Muller, R, Misund, K, Holien, T, Bachke, S, Gilljam, KM, Våtsveen, TK, , TB, Bellacchio, E, Sundan, A and Otterlei, M (2013) Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One 8, e70430.CrossRefGoogle ScholarPubMed
Muxel, SM, Aoki, JI, Fernandes, JC, Laranjeira-Silva, MF, Zampieri, RA, Acuña, SM, Müller, KE, Vanderlinde, RH and Floeter-Winter, LM (2018) Arginine and polyamines fate in Leishmania infection. Frontiers in Microbiology 8, 2682.CrossRefGoogle ScholarPubMed
Nair, A, Chakraborty, S, Banerji, LA, Srivastava, A, Navare, C and Saha, B (2020) Ras isoforms: signaling specificities in CD40 pathway. Cell Communication and Signaling 18, 112.CrossRefGoogle ScholarPubMed
Naryzhny, SN and Lee, H (2007) Characterization of proliferating cell nuclear antigen (PCNA) isoforms in normal and cancer cells: there is no cancer-associated form of PCNA. FEBS Letters 581, 49174920.CrossRefGoogle ScholarPubMed
Nguewa, PA, Fuertes, MA, Iborra, S, Najajreh, Y, Gibson, D, Martínez, E, Alonso, C and Pérez, JM (2005) Water soluble cationic trans-platinum complexes which induce programmed cell death in the protozoan parasite Leishmania infantum. Journal of Inorganic Biochemistry 99, 727736.CrossRefGoogle ScholarPubMed
Nguewa, PA, Villa, TG and Notario, V (2016) Microbiome control in the prevention and early management of cancer. In Villa, T and Vinas, M (eds), New Weapons to Control Bacterial Growth. Cham: Springer, pp. 219237. https://doi.org/10.1007/978-3-319-28368-5_10.CrossRefGoogle Scholar
Nicolas, G, Elliott Koury, DO, Salibi, C, Nehme, L, Mitri, S, El Sayegh, JSA, Rached, L and Khoury, G (2018) Leishmania in a patient with small lymphocytic lymphoma/chronic lymphocytic leukemia. The American Journal of Case Reports 19, 512516.CrossRefGoogle Scholar
Nucci, M and Anaissie, E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clinical Infectious Diseases 49, 12111225.CrossRefGoogle ScholarPubMed
Nweze, JA, Nweze, EI and Onoja, US (2020) Nutrition, malnutrition, and leishmaniasis. Nutrition (Burbank, Los Angeles County, Calif.) 73, 110712.CrossRefGoogle ScholarPubMed
Oberley, LW and Buettner, GR (1979) Role of superoxide dismutase in cancer: a review. Cancer Research 39, 11411149.Google ScholarPubMed
Oetken, T, Hiscox, B, Orengo, I and Rosen, T (2017) Cutaneous leishmaniasis mimicking squamous cell carcinoma. Dermatology Online Journal 23, 14.CrossRefGoogle ScholarPubMed
Opperdoes, FR and Szikora, JP (2006) In silico prediction of the glycosomal enzymes of Leishmania major and trypanosomes. Molecular and Biochemical Parasitology 147, 193206.CrossRefGoogle ScholarPubMed
Palma, LC, Ferreira, LFGR, Petersen, A, Dias, BRS, de Menezes, JPB, de Magalhães Moreira, DR, Hernandes, MZ and Veras, PST (2019) A docking-based structural analysis of geldanamycin-derived inhibitor binding to human or Leishmania HSP90. Scientific Reports 9, 19.CrossRefGoogle ScholarPubMed
Paramchuk, WJ, Ismail, SO, Bhatia, A and Gedamu, L (1997) Cloning, characterization and overexpression of two iron superoxide dismutase cDNAs from Leishmania chagasi: role in pathogenesis. Molecular and Biochemical Parasitology 90, 203221.CrossRefGoogle ScholarPubMed
Perdeh, J, Berioso, B, Love, Q, LoGiudice, N, Le, TL, Harrelson, JP and Roberts, SC (2020) Critical functions of the polyamine putrescine for proliferation and viability of Leishmania donovani parasites. Amino Acids 52, 261274.CrossRefGoogle ScholarPubMed
Pérez-Pertejo, Y, Escudero-Martínez, JM, Reguera, RM, Balaña-Fouce, R, García, PA, Jambrina, PG, San Feliciano, A and Castro, MA (2019) Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB international. Journal for Parasitology: Drugs and Drug Resistance 11, 7079.Google Scholar
Perez, EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Molecular Cancer Therapeutics 8, 20862095.CrossRefGoogle ScholarPubMed
Perez, JM, Fuertes, MA, Nguewa, PA, Castilla, J and Alonso, C (2008) Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Current Medicinal Chemistry 15, 433439.CrossRefGoogle Scholar
Petersen, A, Campos, TA, Dantas, D, Rebouças, J, da Silva, JC, de Menezes, JP, Formiga, FR, de Melo, JV, Machado, G and Veras, PS (2018) Encapsulation of the HSP90 chaperone inhibitor 17-AAG in stable liposome allow increasing the therapeutic index as assessed, in vitro, on Leishmania (L) amazonensis amastigotes-hosted in mouse CBA macrophages. Frontiers in Cellular and Infection Microbiology 8, 303.CrossRefGoogle ScholarPubMed
Pires, VC, Magalhaes, CP, Ferrante, M, de Souza Rebouças, J, Nguewa, P, Severino, P, Barral, A, Veras, PST and Formiga, FR (2020) Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against Leishmania infections: preparation, characterization and macrophage uptake. Acta Tropica 211, 105595.CrossRefGoogle ScholarPubMed
Piro, E, Kropp, M, Cantaffa, R, Lamberti, AG, Carillio, G and Molica, S (2012) Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib. Annals of Hematology 91, 18271828.CrossRefGoogle Scholar
Pommier, Y, Sun, Y, Shar-yin, NH and Nitiss, JL (2016) Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nature Reviews Molecular Cell Biology 17, 703721.CrossRefGoogle ScholarPubMed
Ponte-Sucre, A, Campos, Y, Fernandez, M, Moll, H and Mendoza-León, A (1998) Leishmania sp.: growth and survival are impaired by ion channel blockers. Experimental Parasitology 88, 1119.CrossRefGoogle ScholarPubMed
Prada, CF, Alvarez-Velilla, R, Balana-Fouce, R, Prieto, C, Calvo-Alvarez, E, Escudero-Martínez, JM, Requena, JM, Ordóñez, C, Desideri, A and Perez-Pertejo, Y (2013) Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. Biochemical Pharmacology 85, 14331440.CrossRefGoogle ScholarPubMed
Prasad, V, Kumar, SS and Dey, CS (2000) Resistance to arsenite modulates levels of α-tubulin and sensitivity to paclitaxel in Leishmania donovani. Parasitology Research 86, 838842.CrossRefGoogle ScholarPubMed
Pusnik, M, Charrière, F, Maser, P, Waller, RF, Dagley, MJ, Lithgow, T and Schneider, A (2009) The single mitochondrial porin of Trypanosoma brucei is the main metabolite transporter in the outer mitochondrial membrane. Molecular Biology and Evolution 26, 671680.CrossRefGoogle ScholarPubMed
Ramazzotti, G, Faenza, I, Follo, MY, Fiume, R, Piazzi, M, Giardino, R, Fini, M and Cocco, L (2011) Nuclear phospholipase C in biological control and cancer. Critical Reviews in Eukaryotic Gene Expression 21, 291301.CrossRefGoogle ScholarPubMed
Ramírez, CA, Requena, JM and Puerta, CJ (2013) Alpha tubulin genes from Leishmania braziliensis: genomic organization, gene structure and insights on their expression. BMC Genomics 14, 454.CrossRefGoogle ScholarPubMed
Ramos, A, Munez, E, García-Domínguez, J, Martinez-Ruiz, R, Chicharro, C, Banos, I, Suarez-Massa, D and Cuervas-Mons, V (2015) Mucosal leishmaniasis mimicking squamous cell carcinoma in a liver transplant recipient. Transplant Infectious Disease 17, 488492.CrossRefGoogle Scholar
Rashidi, S, Mojtahedi, Z, Shahriari, B, Kalantar, K, Ghalamfarsa, G, Mohebali, M and Hatam, G (2019) An immunoproteomic approach to identifying immunoreactive proteins in Leishmania infantum amastigotes using sera of dogs infected with canine visceral leishmaniasis. Pathogens and Global Health 113, 124132.CrossRefGoogle ScholarPubMed
Rashidi, S, Nguewa, P, Mojtahedi, Z, Shahriari, B, Kalantar, K and Hatam, G (2020 a) Identification of immunoreactive proteins in secretions of Leishmania infantum promastigotes: an immunoproteomic approach. Eastern Mediterranean Health Journal 26, 15471554.CrossRefGoogle Scholar
Rashidi, S, Kalantar, K, Nguewa, P and Hatam, G (2020 b) Leishmanial selenoproteins and the host immune system: towards new therapeutic strategies? Transactions of The Royal Society of Tropical Medicine and Hygiene 114, 541544.CrossRefGoogle ScholarPubMed
Ray, S, Sadhukhan, PK, Mandal, NB, Mahato, SB and Majumder, HK (1997) Dual inhibition of DNA topoisomerases of Leishmania donovani by novel indolyl quinolines. Biochemical and Biophysical Research Communications 230, 171175.CrossRefGoogle ScholarPubMed
Ray, S, Hazra, B, Mittra, B, Das, A and Majumder, HK (1998) Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Molecular Pharmacology 54, 994999.CrossRefGoogle ScholarPubMed
Reguera, RM, Álvarez-Velilla, R, Domínguez-Asenjo, B, Gutiérrez-Corbo, C, Balaña-Fouce, R, Cushman, M and Pérez-Pertejo, Y (2019) Antiparasitic effect of synthetic aromathecins on Leishmania infantum. BMC Veterinary Research 15, 405.CrossRefGoogle ScholarPubMed
Reimão, JQ, Mesquita, JT, Ferreira, DD and Tempone, AG (2016) Investigation of calcium channel blockers as antiprotozoal agents and their interference in the metabolism of Leishmania (L.) infantum. Evidence-Based Complementary and Alternative Medicine 2016, 1523691.CrossRefGoogle Scholar
Requena, JM, Montalvo, AM and Fraga, J (2015) Molecular chaperones of Leishmania: central players in many stress-related and-unrelated physiological processes. BioMed Research International 2015, 301326.CrossRefGoogle Scholar
Roy, SK, Shrivastava, A, Srivastav, S, Shankar, S and Srivastava, RK (2020) SATB2 is a novel biomarker and therapeutic target for cancer. Journal of Cellular and Molecular Medicine 24, 1106411069.CrossRefGoogle ScholarPubMed
R Woodford, M, Dunn, DM, Ciciarelli, JG, Beebe, K, Neckers, L and Mollapour, M (2016) Targeting HSP90 in non-cancerous maladies. Current Topics in Medicinal Chemistry 16, 27922804.CrossRefGoogle Scholar
Safarzadeh, A, Alizadeh, M, Beyranvand, F, Jozaaee, RF, Hajiasgharzadeh, K, Baghbanzadeh, A, Derakhshani, A, Argentiero, A, Baradaran, B and Silvestris, N (2020) Varied functions of immune checkpoints during cancer metastasis. Cancer Immunology, Immunotherapy 69, 120.Google Scholar
Sagar, S, Kaur, M, Minneman, KP and Bajic, VB (2010) Anti-cancer activities of diospyrin, its derivatives and analogues. European Journal of Medicinal Chemistry 45, 35193530.CrossRefGoogle ScholarPubMed
Saha, S, Basu, M, Guin, S, Gupta, P, Mitterstiller, AM, Weiss, G, Jana, K and Ukil, A (2019) Leishmania donovani exploits macrophage heme oxygenase-1 to neutralize oxidative burst and TLR signaling-dependent host defense. The Journal of Immunology 202, 827840.CrossRefGoogle ScholarPubMed
Sanchez-Moreno, M, Gomez-Contreras, F, Navarro, P, Marin, C, Ramírez-Macías, I, Rosales, M, Campayo, L, Cano, C, Sanz, A and Yunta, M (2015) Imidazole-containing phthalazine derivatives inhibit Fe-SOD performance in Leishmania species and are active in vitro against visceral and mucosal leishmaniasis. Parasitology 142, 11151129.CrossRefGoogle ScholarPubMed
Sarkar, D, Leung, EY, Baguley, BC, Finlay, GJ and Askarian-Amiri, ME (2015) Epigenetic regulation in human melanoma: past and future. Epigenetics 10, 103121.CrossRefGoogle ScholarPubMed
Sauter, IP, Madrid, KG, de Assis, JB, Sá-Nunes, A, Torrecilhas, AC, Staquicini, DI, Pasqualini, R, Arap, W and Cortez, M (2019) TLR9/MyD88/TRIF signaling activates host immune inhibitory CD200 in Leishmania infection. JCI Insight 4, e126207.CrossRefGoogle ScholarPubMed
Saxena, A, Lahav, T, Holland, N, Aggarwal, G, Anupama, A, Huang, Y, Volpin, H, Myler, P and Zilberstein, D (2007) Analysis of the Leishmania donovani transcriptome reveals an ordered progression of transient and permanent changes in gene expression during differentiation. Molecular and Biochemical Parasitology 152, 5365.CrossRefGoogle ScholarPubMed
Schaefer-Klein, J, Murphy, SJ, Johnson, SH, Vasmatzis, G and Kovtun, IV (2015) Topoisomerase 2 alpha cooperates with androgen receptor to contribute to prostate cancer progression. PLoS One 10, e0142327.CrossRefGoogle ScholarPubMed
Schechter, P, Barlow, J and Sjoerdsma, A (1987) Clinical aspects of inhibition of ornithine decarboxylase with emphasis of therapeutic trials of eflornithine (DFMO) in cancer and protozoan diseases. In Grenfell, B. T. and Dobson, A. P. (eds), Inhibition of Polyamine Metabolism. Academic Press, pp. 345364CrossRefGoogle Scholar
Schwing, A, Pomares, C, Majoor, A, Boyer, L, Marty, P and Michel, G (2019) Leishmania infection: misdiagnosis as cancer and tumor-promoting potential. Acta Tropica 197, 104855.CrossRefGoogle ScholarPubMed
Seng, HL and Tiekink, ER (2012) Anti-cancer potential of selenium-and tellurium-containing species: opportunities abound!. Applied Organometallic Chemistry 26, 655662.CrossRefGoogle Scholar
Sengupta, T, Mukherjee, M, Das, A, Mandal, C, Das, R, Mukherjee, T and Majumder, HK (2005) Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide. Biochemical Journal 390, 419426.CrossRefGoogle ScholarPubMed
Sett, R, Basu, N, Ghosh, AK and Das, PK (1992) Potential of doxorubicin as an antileishmanial agent. The Journal of Parasitology 78, 350354.CrossRefGoogle ScholarPubMed
Sharlow, ER, Leimgruber, S, Murray, S, Lira, A, Sciotti, RJ, Hickman, M, Hudson, T, Leed, S, Caridha, D and Barrios, AM (2014) Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity. ACS Chemical Biology 9, 663672.CrossRefGoogle ScholarPubMed
Sharma, P, Garg, N, Sharma, A, Capalash, N and Singh, R (2019) Nucleases of bacterial pathogens as virulence factors, therapeutic targets and diagnostic markers. International Journal of Medical Microbiology 309, 151354.CrossRefGoogle ScholarPubMed
Sherman, M and Multhoff, G (2007) Heat shock proteins in cancer. Annals of the New York Academy of Sciences 1113, 192201.CrossRefGoogle ScholarPubMed
Shoshan-Barmatz, V, Israelson, A, Brdiczka, D and Sheu, S (2006) The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death. Current Pharmaceutical Design 12, 22492270.CrossRefGoogle ScholarPubMed
Shoshan-Barmatz, V, Krelin, Y, Shteinfer-Kuzmine, A and Arif, T (2017) Voltage-dependent anion channel 1 as an emerging drug target for novel anti-cancer therapeutics. Frontiers in Oncology 7, 154.CrossRefGoogle ScholarPubMed
Shukla, AK, Patra, S and Dubey, VK (2011) Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of Leishmaniasis. Molecular and Cellular Biochemistry 352, 261270.CrossRefGoogle ScholarPubMed
Silva-Barrios, S and Stager, S (2017) Protozoan parasites and type I IFNs. Frontiers in Immunology 8, 14.CrossRefGoogle ScholarPubMed
Silvers, MA, Deja, S, Singh, N, Egnatchik, RA, Sudderth, J, Luo, X, Beg, MS, Burgess, SC, DeBerardinis, RJ and Boothman, DA (2017) The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1 + pancreatic cancer cells, causing perturbation in central carbon metabolism. Journal of Biological Chemistry 292, 1820318216.CrossRefGoogle ScholarPubMed
Singh, G and Dey, CS (2007) Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant L. donovani. Acta Tropica 103, 172185.CrossRefGoogle ScholarPubMed
Singh, G, Thakur, M, Chakraborti, PK and Dey, CS (2009) Evidence for the presence of R250G mutation at the ATPase domain of topoisomerase II in an arsenite-resistant Leishmania donovani exhibiting a differential drug inhibition profile. International Journal of Antimicrobial Agents 33, 8085.CrossRefGoogle Scholar
Slunt, KM, Grace, JM, Macdonald, TL and Pearson, RD (1996) Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrobial Agents and Chemotherapy 40, 706709.CrossRefGoogle ScholarPubMed
Soni, S, Anand, P and Padwad, YS (2019) MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression. Journal of Experimental & Clinical Cancer Research 38, 121.CrossRefGoogle ScholarPubMed
Souza-Silva, F, Bourguignon, SC, Pereira, BAS, de Castro Côrtes, LM, de Oliveira, LFG, Henriques-Pons, A, Finkelstein, LC, Ferreira, VF, Carneiro, PF and de Pinho, RT (2015) Epoxy-α-lapachone has in vitro and in vivo anti-Leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite. Antimicrobial Agents and Chemotherapy 59, 19101918.CrossRefGoogle ScholarPubMed
Spadaro, F, Ramoni, C, Mezzanzanica, D, Miotti, S, Alberti, P, Cecchetti, S, Iorio, E, Dolo, V, Canevari, S and Podo, F (2008) Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Research 68, 65416549.CrossRefGoogle ScholarPubMed
Sprooten, J, Agostinis, P and Garg, AD (2019) Type I interferons and dendritic cells in cancer immunotherapy. International Review of Cell and Molecular Biology 348, 217262.CrossRefGoogle ScholarPubMed
Stevens, M, Abdeen, S, Salim, N, Ray, AM, Washburn, A, Chitre, S, Sivinski, J, Park, Y, Hoang, QQ and Chapman, E (2019) HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules. Bioorganic & Medicinal Chemistry Letters 29, 11061112.CrossRefGoogle ScholarPubMed
Su, TR, Lin, JJ, Chiu, CC, Chen, JYF, Su, JH, Cheng, ZJ, Hwang, WI, Huang, HH and Wu, YJ (2012) Proteomic investigation of anti-tumor activities exerted by sinularin against A 2058 melanoma cells. Electrophoresis 33, 11391152.CrossRefGoogle Scholar
Sun, Y, Liu, Z, Zou, X, Lan, Y, Sun, X, Wang, X, Zhao, S, Jiang, C and Liu, H (2015) Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer. Journal of Bioenergetics and Biomembranes 47, 319329.CrossRefGoogle Scholar
Sundar, S and Olliaro, PL (2007) Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Therapeutics and Clinical Risk Management 3, 733.Google ScholarPubMed
Syu, G-D, Dunn, J and Zhu, H (2020) Developments and applications of functional protein. Microarrays Molecular & Cellular Proteomics 19, 916927.CrossRefGoogle Scholar
Tandon, R, Chandra, S, Baharia, RK, Das, S, Misra, P, Kumar, A, Siddiqi, MI, Sundar, S and Dube, A (2014) Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance. Antimicrobial Agents and Chemotherapy 58, 29973007.CrossRefGoogle ScholarPubMed
Tang, SJ, Ho, MY, Cho, HC, Lin, YC, Sun, GH, Chi, KH, Wang, YS, Jhou, RS, Yang, W and Sun, KH (2008) Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. International Journal of Cancer 123, 28402848.CrossRefGoogle ScholarPubMed
Tataranni, T and Piccoli, C (2019) Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxidative Medicine and Cellular Longevity 2019, 114.CrossRefGoogle ScholarPubMed
Thompson, MD and Monga, SP (2007) WNT/Β-catenin signaling in liver health and disease. Hepatology 45, 12981305.CrossRefGoogle ScholarPubMed
Toogeh, G, Shirkoohi, R, Nickbin, M, Najafi, S, Salimi, M, Farsi, L and Ferdowsi, S (2010) Visceral leishmaniasis presented as myelofibrosis and low grade lymphoma in a sporadic region of Iran, report a rare case. International Journal of Hematology-Oncology and Stem Cell Research 4, 3639.Google Scholar
Torre, LA, Siegel, RL, Ward, EM and Jemal, A (2016) Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiology and Prevention Biomarkers 25, 1627.CrossRefGoogle ScholarPubMed
Torres-Guerrero, E, Quintanilla-Cedillo, MR, Ruiz-Esmenjaud, J and Arenas, R (2017) Leishmaniasis: a review. F1000Research 6, 750.CrossRefGoogle ScholarPubMed
Torti, L, Pulini, S, Morelli, AM, Bacci, F and Di Bartolomeo, P (2015) Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and ‘novel agent’ therapy. International Journal of Hematology 102, 391393.CrossRefGoogle Scholar
Tretina, K, Gotia, HT, Mann, DJ and Silva, JC (2015) Theileria-transformed bovine leukocytes have cancer hallmarks. Trends in Parasitology 31, 306314.CrossRefGoogle ScholarPubMed
Tsai, YP, Yang, MH, Huang, CH, Chang, SY, Chen, PM, Liu, CJ, Teng, SC and Wu, KJ (2009) Interaction between HSP60 and β-catenin promotes metastasis. Carcinogenesis 30, 10491057.CrossRefGoogle ScholarPubMed
Tsourlakis, MC, Weigand, P, Grupp, K, Kluth, M, Steurer, S, Schlomm, T, Graefen, M, Huland, H, Salomon, G and Steuber, T (2014) βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. The American Journal of Pathology 184, 609617.CrossRefGoogle ScholarPubMed
Tsujii, M and DuBois, RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493501.CrossRefGoogle ScholarPubMed
Tsujii, M, Kawano, S, Tsuji, S, Sawaoka, H, Hori, M and DuBois, RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705716.CrossRefGoogle ScholarPubMed
Umejiego, NN, Gollapalli, D, Sharling, L, Volftsun, A, Lu, J, Benjamin, NN, Stroupe, AH, Riera, TV, Striepen, B and Hedstrom, L (2008) Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis. Chemistry & Biology 15, 7077.CrossRefGoogle Scholar
Van Assche, T, Deschacht, M, da Luz, RAI, Maes, L and Cos, P (2011) Leishmania-macrophage interactions: insights into the redox biology. Free Radical Biology and Medicine 51, 337351.CrossRefGoogle ScholarPubMed
Vasconcelos, G, Azevedo-Silva, F, Thuler, L, Pina, ETG, Souza, CS, Calabrese, K and Pombo-de-Oliveira, MS (2014) The concurrent occurrence of Leishmania chagasi infection and childhood acute leukemia in Brazil. Revista Brasileira de Hematologia e Hemoterapia 36, 356362.CrossRefGoogle ScholarPubMed
Vassalli, G (2019) Aldehyde dehydrogenases: not just markers, but functional regulators of stem cells. Stem Cells International 2019, 3904645.CrossRefGoogle ScholarPubMed
Viana, AG, Magalhães, LMD, Giunchetti, RC, Dutra, WO and Gollob, KJ (2019) Leishmania infantum induces expression of the negative regulatory checkpoint, CTLA-4, by human naïve CD8 + T cells. Parasite Immunology 41, e12659.CrossRefGoogle ScholarPubMed
Vieira, L, Lavan, A, Dagger, F and Cabantchik, Z (1994) The role of anions in pH regulation of Leishmania major promastigotes. Journal of Biological Chemistry 269, 1625416259.CrossRefGoogle ScholarPubMed
Wang, JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nature Reviews Molecular Cell Biology 3, 430440.CrossRefGoogle ScholarPubMed
Watson, HC and Littlechild, JA (1990) Isoenzymes of phosphoglycerate kinase: evolutionary conservation of the structure of this glycolytic enzyme. Biochemical Society Transactions 18, 187190.CrossRefGoogle ScholarPubMed
Willson, M, Callens, M, Kuntz, DA, Perié, J and Opperdoes, FR (1993) Synthesis and activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. Molecular and Biochemical Parasitology 59, 201210.CrossRefGoogle ScholarPubMed
Wood, L, Leese, MP, Leblond, B, Woo, L, Ganeshapillai, D, Purohit, A, Reed, MJ, Potter, BV and Packham, G (2001) Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. Anti-Cancer Drug Design 16, 209215.Google ScholarPubMed
Xu, S, Butkevich, AN, Yamada, R, Zhou, Y, Debnath, B, Duncan, R, Zandi, E, Petasis, NA and Neamati, N (2012) Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proceedings of the National Academy of Sciences 109, 1634816353.CrossRefGoogle ScholarPubMed
Xu, S, Sankar, S and Neamati, N (2014) Protein disulfide isomerase: a promising target for cancer therapy. Drug Discovery Today 19, 222240.CrossRefGoogle ScholarPubMed
Yamashita, M, Tahara, T, Hayakawa, S, Matsumoto, H, Wada, S-i, Tomioka, K and Iida, A (2018) Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-targeted inhibitors. Bioorganic & Medicinal Chemistry 26, 19201928.CrossRefGoogle ScholarPubMed
Yan, J, Guo, Y, Wang, Y, Mao, F, Huang, L and Li, X (2015) Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents. European Journal of Medicinal Chemistry 95, 220229.CrossRefGoogle ScholarPubMed
Yang, W, Shin, H-Y, Cho, H, Chung, J-Y, Lee, E-j, Kim, J-H and Kang, E-S (2020) TOM40 inhibits ovarian cancer cell growth by modulating mitochondrial function including intracellular ATP and ROS levels. Cancers 12, 1329.CrossRefGoogle ScholarPubMed
You, BR and Park, WH (2016) Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion. Oncology Reports 35, 546551.CrossRefGoogle ScholarPubMed
Younus, H (2018) Therapeutic potentials of superoxide dismutase. International Journal of Health Sciences 12, 88.Google ScholarPubMed
Zarsky, V, Tachezy, J and Dolezal, P (2012) TOM40 is likely common to all mitochondria. Current Biology 22, R479R481.CrossRefGoogle ScholarPubMed
Zigmond, E, Ya'acov, AB, Lee, H, Lichtenstein, Y, Shalev, Z, Smith, Y, Zolotarov, L, Ziv, E, Kalman, R and Le, HV (2015) Suppression of hepatocellular carcinoma by inhibition of overexpressed ornithine aminotransferase. ACS Medicinal Chemistry Letters 6, 840844.CrossRefGoogle ScholarPubMed
Zininga, T and Shonhai, A (2019) Small molecule inhibitors targeting the heat shock protein system of human obligate protozoan parasites. International Journal of Molecular Sciences 20, 5930.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Some common compounds used against cancer and leishmaniasis

Figure 1

Table 2. Possible functions of several common proteins expressed in Leishmania parasites and cancer cells and plausible inhibitors/drugs against such proteins